manejo del dolor con medicamentos guna
TRANSCRIPT
C O M P L E M E N T O S C O N M E D I C A M E N T O S E U R O L I F E
F E L I P E T O R R E S M D .M . R . F . , T e r a p i a C e l u l a r
F E L I P E T O R R E S M D .M . R . F . , T e r a p i a C e l u l a r
E L D O L O R
R . P . M
M E D I C A M EN T O S
C O M P L E ME N T O S
E l d o l o r e s u n a s e n s a c i ó n s u b j e t i v a , p o l i m o r f a y m u l t i d i m e n s i o n a l . D i f í c i l d e c u a n t i f i c a r.
I N T R O D U C C IÓ N
S E N S A C I Ó N S U B J E T I V A :
M e z c l a l a p e r c e p c i ó n y l a e s t r u c t u r a p s i c o l ó g i c a d e l s u j e t o .
I N T R O D U C C IÓ N
I N T R O D U C C IÓ N
L a n o c i c e p c i ó nc o m p r e n d e d o s e t a p a s :
1 - L a t r a n s d u c c i ó n d e l e s t í m u l o n o c i v o p o r l a s t e r m i n a c i o n e s n e r v i o s a s p e r i f é r i c a s
2 - L a t r a n s m i s i ó n d e e s a s s e ñ a l e s h a c i a e l s i s t e m a n e r v i o s o c e n t r a l .
E l im p u l s o n o c i c e p t i v os e m o d u l a e n c a d a n i v e l d e l a v í a s e n s i t i v a
F I S I O L O G Í A D E L D O L O R
D I F E R E N T E S T IP O SD E D O L O R :
- A G U D O : S ea c o m p a ñ a d er e a c c i o n e ss o m a t o e g e t a t i v a s yd e a n s i e d a d .
- C R O N I C O ( m á s d e 6m e s e s ) : S e a c o m p a ñ ad e t e n d e n c i a sd e p r e s i v a s ,i r r i t a b i l i d a d ,t r a s t o r n o s d e l s u e ñ o ,d e l a p e t i t o y d e l a
I N T R O D U C C IÓ N
L o s d o l o r e s s o n c l a s i f i c a d o s , d e a c u e r d o c o n s u o r i g e n , e n :
C A R A C T E R Í S T I C A S D E L D O L O R
S O M ÁT I C O S
V I S C E R A L E S
N E U R Ó G E N O
C u a n d o l a s e n s a c i ó n d o l o r o s a s ep r o d u c e a n i v e l d e l a p i e l , d e la p a r a t o l o c o m o t o r o d e l t e j i d oc o n e c t i v o , s e h a b l a d e d o l o rs o m át i c o .
Pue d e a d o p t a r 2 f o r m a s :
• D o l o r s u p e r f i c i a l : c u a n d o e le s t í m u l o s e l o c a l i z a a n i v e l d e l ap i e l
• D o l o r p r o f u n d o : e l q u e s e p r o d u c ea n i v e l m u s c u l a r, ó s e o o d e l t e j i d oc o n j u n t i v o
S O M ÁT I C O S
C A R A C T E R Í S T I C A S D E L D O L O R
E l d o l o r su p e r f i c i a l , q u e s e p r o d u c ep o r e j e m p l o l u e g o d e u n p i n c h a z o ,s e c o m p o n e d e 2 p a r t e s :
- E l p r i m e r d o l o r s u p e r f i c i a l t i e n eu n c a rá c t e r a g u d o , e s b i e nl o c a l i z a d o y d e s a p a r e c erá p i d a m e n t e l u e g o d e f r e n a d o e le s t í m u l o . E s t e e s t í m u l o d o l o r o s os u e l e a c o m p a ñ a r s e d e r e a c c i o n e srá p i d a s d e h u i d a , c o m o e l r e t i r a r e lp i e a l p i s a r u n p e d a z o d e v i d r i o , af i n d e e v i t a r m á s d a ñ o s a l
S O M ÁT I C O S
C A R A C T E R Í S T I C A S D E L D O L O R
- A e s t e d o l o r s u p e r f i c i a l p r i m a r i ol e s i g u e a m e n u d o u n d o l o rs u p e r f i c i a l s e c u n d a r i o , qu e e ng e n e r a l e s d e c a rá c t e r s o r d o ou r e n t e , q u e e s m á s d i f í c i l d el o c a l i z a r y qu e d e s a p a r e c e m á sl e n t a m e n t e . E s t e d o l o r s u p e r f i c i a ls e c u n d a r i o e s n e u r o l ó g i c a m e n t ei d é n t i c o a l d o l o r p r o f u n d o , q u eo r i g i n a , p o r e j e m p l o l a c e f a l e a -u n a d e l a s f o r m a s d e d o l o r m á sc o m ú n q u e a f e c t a a l o s s e r e sh u m a n o s .
S O M ÁT I C O S
C A R A C T E R Í S T I C A S D E L D O L O R
E l c o n t r a p u e s t o a l d o l o r s o m át i c o e se l d o l o r v i s c e r a l .
E s s e m e j a n t e a u n d o l o r d e c a rá c t e rs o r d o y, j u n t o c o n l a s r e a c c i o n e s d et i p o v e g e t a t i v o , a l d o l o r p r o f u n d o .A p a r e c e p o r f r e n t e a l a d i l a t a c i ó n ol o s e s p a s m o s (e n e l d o l o r m e n s t r u a l )d e l a m u s c u l a t u r a l i s a , e n l a sh e m o r r a g i a s y e n l o s p r o c e s o si n f l a m a t o r i o s .
S e p u e d e p r e s e n t a r c o m o d o l o rd u r a d e r o c o m o e n l o s d o l o r e se s t o m a c a l e s o d e t i p o p e r i ó d i c o
V I S C E R A L E S
C A R A C T E R Í S T I C A S D E L D O L O R
J u n t o a l d o l o r s o m á t i c o y a l v i s c e r a ls e p u e d e p r e s e n t a r f i n a l m e n t e e ld o l o r n e u r ó g e n o .
S e o r i g i n a p o r e l e s t í m u l o d e f i b r a sn e r v i o s a s , c u a n d o l a s m i s m a s s o nd a ñ a d a s o i n t e r r u m p i d a s ,p r e s e n t a n d o u n c a r ác t e r a g u d o .
E j e m p l o s d e e s t e t i p o d e d o l o r e s l an e u r a l g i a d e l t r i g é m i n o y e l d o l o rf a n t a s m a l u e g o d e a m p u t a c i o n e s : e li n d i v i d u o a f e c t a d o r e f i e r e d o l o r d e lm i e m b r o a m p u t a d o . E l e s t í m u l od o l o r o s o s e o r i g i n a a n i v e l d e l m u ñ ó n
N E U R Ó G E N O
C A R A C T E R Í S T I C A S D E L D O L O R
A d e m ás d e s u o r i g e n e l d o l o r p u e d e d i f e r e n c i a r s e d e a c u e r d o c o n s u
d u r a c i ó n :
C A R A C T E R Í S T I C A S D E L D O L O R
A G U D O
C R Ó N I C O
El d o l o r agu d o t i e n e u n t i e m p ol i m i t a d o , d e s a p a r e c i e n d orá p i d a m e n t e . E s t e d o l o r p u e d et o l e r a r s e i n c l u s o s i n m e d i c a m e n t o sc o m o e n l o s t r a t a m i e n t o so d o n t o l ó g i c o s .
A G U D O
C A R A C T E R Í S T I C A S D E L D O L O R
El d o l o r c r ó n i c o p u e d e p r e s e n t a r s ec o m o d u r a d e r o e n e l d o l o r l u m b a r ot u m o r a l o r e c u r r e n t e c o m o e n l a sc e f a l e a s o a n g i n a d e p e c h o ) . L o sd o l o r e s c r ó n i c o s s o n e n g e n e r a ld i f í c i l e s d e t o l e r a r.
C R Ó N I C O
N o t o d o s l o s d o l o r e s t i e n e n s u o r i g e n e n l o s r e c e p t o r e s d o l o r o s o s :
C A R A C T E R Í S T I C A S D E L D O L O R
PS I C Ó G E N O
A v e c e s p u e d e p r e v a l e c e r u n aa f e c c i ó n p s i c o l ó g i c a , e n l a c u a l e lp a c i e n t e n o p u e d e m a n i f e s t a r s u sc o n f l i c t o s d e o t r a m a n e r a q u er e f i r i e n d o d o l o r e s .
L a a f e c c i ó n p s i c o l ó g i c a p u e d ep r e s e n t a r s e b a j o u n a f o r m as o m át i c a , c o m o u n d o l o r.
PS I C Ó G E N O
C A R A C T E R Í S T I C A S D E L D O L O R
I N T R O D U C C I Ó N
MECANISMOS PERIFERICOS: SENSIBIL IDAD PUNTUAL DE L A PIEL
E l exá m e n d e l a s e n s i b i l i d a d d e l ap i e l a e s t í m u l o s m u y l o c a l i z a d o sp e r m i t e o b s e r v a r q u e l a s e n s i b i l i d a dv a r í a d e u n p u n t o a o t r o ; m u y b a j a e na l g u n o s p u n t o s y m u y e l e v a d a e no t r o s .
T a m b i é n s e h a p o d i d o e s t a b l e c e l ae x i s t e n c i a d e p u n t o s c u t án e o s q u er e s p o n d e n a l t a c t o , a l f r í o , a l c a l o r ya a l d o l o r.
Pa r a c a d a t i p o d e s e n s a c i ó n s e h a nd i b u j a d o m a p a s p a r a c a d a r e g i ó n
INTERVENCIONES TERAPÉUTICAS: NIVEL PERIFÉRICO
E n c a d e n a m i e n t o n e u r o n a l r e s p o n s a b l e d e l a t r a n s m i s i ó n d e l a i n f o r m a c i ó n a l o s c e n t r o s
I N T R O D U C C I Ó N
E x i s t e n u n a c a t e g o r í a d e r e c e p t o r e sq u e n o p u e d e n s e r e s t i m u l a d o s m á sq u e p o r e s t í m ulo s i n t e n s o s d e o r i g e nd i v e r s o s . E s t a s e s t i m u l a c i o n e sp u e d e n s e r r e a l i z a d a s e n t r e sc o n d i c i o n e s :
1 - L e s i ó n t i s u l a r o r i g i n a d a p o rp u n c i ó n , p r e s i ó n , r o t u r a oqu e m a d u r a .
2 - I n f l a m a c i ó n t i s u l a r c o n s e c u e n t ed e l a s a n t e r i o r e s o d i r e c t a m e n t ep r o v o c a d a p o r a g e n t e s q u í m i c o se xó g e n o s o e n d ó g e n o s .
N O C I C E PT O R E S
N O C I C E PT O R E S
A p e s a r d e l a d i v e r s i d a d d e l o se s t í m u l o s , e s p o s i b l e h a b l a r d en o c i c e p t o r e s d e l a n t e d e l o s c r i t e r i o ss i g u i e n t e s (definidos por Iggo):
U mb r a l a e s t í m u l o s e l e v a d o : e s t o s ea p l i c a , s o b r e t o d o , an o c i c e p t o r e s m e c á n i c o s o t é r m i c o sc u y o u m b r a l e l e v a d oc o n t r a s t a c o n e l u m b r a l b a j o d e l o sm e c a n o o d e l o st e r m o r e c e p t o r e s e s p e c í f i c o s .
Pequ eñ a su p e r f i c i e d e l c a m p or e c e p t o r.
D e s c a r g a d e t i p o t ó n i c o , p o c oa d a p t a b l e , p e r s i s t e n t e d e s p u é sd e la p a r a d a d e l e s t í m u l o .
I n e r v a c i ó n p o r f ib r a s d e p e qu eñ od i ám e t r o (A d e l t a y C ).
A R E A IN F L A M A D A
S U S T A N C I A S A L G O G E N A S
KININAS: S o n u n g r u p o d e s u s t a n c i a sq u e t a m b i é n a c t ú a n c o m om e d i a d o r e s d e la in f l a m a c i ó n :
- BRADIKININA: S e l i b e r a e n l a sq u e m a d u r a s c u tá n e a s . L ai n y e c c i ó n l o c a l e n e l h o m b r ep r o v o c a d o l o r p o r a d e s c a r g a d el a s f i b r a s C .
- PROSTAGANDINAS: L a P G E l y PG E 2 ,i n t e r v i e n e n d e m a n e r a e v i d e n t ee n l a i n f l a m a c i ó n . L a sp e r f u s i o n e s s u b c u tá n e a s d e PG E 1a m u y b a j a s c o n c e n t r a c i o n e s e ne l h o m b r e p r o d u c e n
M A G N E T O T ER A PI A
IM A N E S T E R A PE U T I C O S
NIVEL PERIFERICO: Co n n ut r i e n t e s :
- N u t r i e n t e s qu e i n h i b e n l a s c i t o qu i n a s , p r o s t a g l a n d i n a s y l e u c o t r i e n o s .
- N u t r i e n t e s qu e i n t e r v i e n e n e n l a r e p a r a c i ó n d e l o s t e j i d o s d a ñ a d o sp o r l a i n f l a m a c i ó n .
- N u t r i e n t e s d e a p o y o a n t i o xi d a n t e .
I N T E R V E N C I O N E S T E R A PÉU T I C A S
S i g u i e n d o l a r e a c c i ó n d e B y s t a n d e r
I N T E R V E N C I O N E S T E R A PÉU T I C A SN I V E L PE R I F E R I C O : C o n C o m p l e j o s Ho m e o p át i c o s :
InmunologiaInmunologia
L a inflamación periférica es regulada por el S .N .C .
L a a f i n i d a d d e l T C R , p o r lo s c o m p l e jo s p e p t íd i c o s a s o c i a d o s a l
M H C , a u m e n t a e n la m e d i d a e n qu e lo s c o n t a c t o s s e a n m a s
r e p e t i t i v o s .
InmunologiaInmunologia
E l in t e r f e r o n ( I F N ) s e g a m a o b e t a s e p r o d u c e n b ás i c a m e n t e p o r e l e s t i m u l o d e a n t i g e n o s
v i r a l e s .
E l M A L T s e c r e t a
T G F b e t a -1 , qu e
in d u c e la p r o d u c c i ó
n le l i n f o c i t o B
e Ig A .
E l T N F - a l f a y la IL - 1 e s
e s t i m u l a d o s p o r
l i p o p o l i s a c ar i d o s
b a c t e r i a n o s y e n m e n o r
e s t ím u l o s a n t i g e n o s
v i r a l e s .
InmunologiaInmunologia
S e p u e d e s u f r i r e l s ín d r o m e d e l a s m u c o s a s p a r c i a l o
t o t a l m e n t e , s e g ún e l n u m e r o d e m u c o s a s
c o m p r o m e t i d a s .
InmunologiaInmunologia
E l M A L T , s e c o n s i d e r a u n
ór g a n o l i n f o i d e e n t r e la s
m u c o s a s , e n la s qu e in t e r v i e n e n
la s m u c o s a s r e s p i r a t o r i a s y
d i g e s t i v a s , e l T G U c o m p a r t e d r e n a je y la p r e s e n c i a d e
t e ji d o l i n f o i d e s i m i l a r a l in t e s t i n a l .
E l f e n óm e n o d e H o m i n g d e lo s
l e u c o c i t o s , o v o l v e r a l s i t i o
d e s e n s i b i l i z a c i ón
a n t i g én i c a , e x p l i c a la
m a n i f e s t a c i ón f i s i o p a t o l o g i c a
d e l s ín d r o m e d e la s m u c o s a s
InmunologiaInmunologia
P s i c o n e u r o e n d o c r i n o i n m u n o l o gia : in t e r a c c i ón e n t r e lo s
s i s t e m a s n e u r o e n d o c r i n o e in m u n e , a s í c o m o e l e s t u d i o d e lo s c a m b i o s c o n d u c t u a l e s qu e
d i c h a in t e r a c c i ón p r o d u c e .
L a in t e r a c c i ón e s b i d i r e c c i o n a l
InmunologiaInmunologia
I n f l u y e la m e n t e e n la s u s c e p t i b i l i
d a d d e e n f e r m a r , o
e n la f a c i l i d a d
p a r a r e c u p e r a r s e
d e u n a e n f e r m e d a
d ?
E l c e r e b r o y l a
r e s p u e s t a i n m u n e
E l c e r e b r o y l a
r e s p u e s t a i n m u n e
L e s i o n e s d e l h i p o t ál a m o ,
s i s t e m a l i m b i c o , o f o r m a c i ón
r e t i c u l a r
L e s i o n e s d e l h i p o t ál a m o ,
s i s t e m a l i m b i c o , o f o r m a c i ón
r e t i c u l a r
L a t e r a l i z a c i ón h e m i s f ér i c a d e la
r e s p u e s t a in m u n e
L a t e r a l i z a c i ón h e m i s f ér i c a d e la
r e s p u e s t a in m u n e
Sustento inmunológicoSustento inmunológico
Sustento inmunológicoSustento inmunológico
Clonación en ganglios linfáticos.
Son atraídos por quimiotaxis o por organotropismo o histotropismo.
NeuroendocrinoinmunologiaNeuroendocrinoinmunologiaES EL CAMPO CIENTÍFICO INTERDISCIPLINARIO QUE INVESTIGA LAS RELACIONES ENTRE EL CEREBRO ( MENTE-CONDUCTA) Y EL SISTEMA INMUNE Y SUS CONSECUENCIAS CLINICAS
NeuroendocrinoinmunologiaNeuroendocrinoinmunologia
NeuroendocrinoinmunologiaNeuroendocrinoinmunologia
NeuroendocrinoinmunologiaNeuroendocrinoinmunologia
This material is based on the presenter’s studies in PHYSIOLOGICAL REGULATING MEDICINE.
The information presented here is not to be considered a prescription and we do not accept medical or legal responsibility for misuse of the information presented. This information is for educational purposes for licensed health care professionals within their scope of practice.
43© D i p a r t i m e n t o S c i e n t i f i c o
G u n a S . p . a .
1 . L O W D O S E S .K.A . - P R I N C I P L E S O F HO M E O P A T HY
1 . N E W C HE M I C A L S WIT H S .K.A . T E C HO N O L O G Y
1 . C YT O KI N E S : IT S R E L E VA N C E IN P A I N A N D IN F L A M M A T I O N
1 . E XP E R I M E N T A L D A T A T O VA L I D A T E C YT O KI N E P O T E N C Y IN A N I M A L M O D E L
1 . C L I N I C A L A P P L I C A T I O N O F L O W D O S E S .K.A . IN P A I N
What You Will L earn T oday
WE S T E RN
C O N VE NT I O N A L M E D I C I
N E
C O M P L E ME N T A R Y
A L T E R N A TIVE
M E D I C I N E
P h y s i o l o g i c a l R e g u l a t i n g M e d i c i n e
P R M
45© D i p a r t i m e n t o S c i e n t i f i c o
G u n a S . p . a .
Homeopathic S cience M olecular Biology
M I N E R A L ,P L A N T ,
A N I M A L D E R I VA T I VE
S
N E U R O P E PT I D E S ,
C YT O KI N E S , HO R M O N E S ,
G R O WT H F A C T O R S
P R M D R U G SA new pharmacological concept: one biotherapeutic medicine blending synergistic ingredients from Complementary Alternative Medicine and Conventional Medicine to achieve a positive clinical outcome.
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
PHY SI OL OG I CA L REG U L A TI NG MEDICI NE (PRM)
T he science of P R M integrates state of the art scientific advances in:
• Homeopathy• Homotoxicology• P sycho N euro E ndocrine Immunology (P N E I )• N utritional and P hyto- M edicineTo formulate biotherapeutic medicines achieving the best individualized prescription for patients to promote recovery from illness and restoration of health
P .N .E .I .
M o l ec u l a r Bio l o
g yN u t r it i o n a l M e d ic i n e
H o m eo p a t h
yH o m o t ox i c o l o g y
Qu a nt u m P h y s
ic s
©
Dip
ar
tim
en
to
S
cie
nt
ific
o
Gu
na
S
.p.a
.
PNEI
C E N T R A L N E R VO U S
S YS T E M&
N E U R O VE G E T A T IVE S YS T E M S
IM M U N E S YS T E M
E N D O C R I N E S YS T E M
Homeostatic control systems
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
A d e r , R . , P s y c h o n e u r o i m m u n o l o g y , IV e d i t i o n , v o l . 1 e 2 , A c a d e m i c P r e s s , A m s t e r d a m 2 0 0 7. I t is th e c l a s s i c a l t e x t o n t h e m a t t e r , p u b b l i s h e d fo r
D a : P s i c o N e u r o E n d o c r i n o I m m u n o l o g i a . F r a n c e s c o Bo t t a c c i o l i – R E D E d i z i o n i
T h e h o r m o n e s in f l u e n c e c y t o k i n e s l e v e l s a n d r e a l i z e a c o n n e c t i o n b e t w e e n e n d o c r i n e s y s t e m a n d im m u n e s y s t e m◦ F E M A L E S E XU A L H O R M O N E S
i n h i b i t t h e T h 2 r e a c t i o n a n d s t i m u l a t e T h 1 c y t o k i n e s
◦ C O R T I S O L in h i b i t t h e T h 1 r e a c t i o n a n d i n p a r t i c u l a r I L -2 . In t u r n , d i f f e r e n t i n t e r l e u k i n s , a m o n g w h i c h I L -
◦ I L - 1 , T N F - α, I F N - γa n d in p a r t i c u l a r I L -6 h a v e a f u n d a m e n t a l r o l e in t h e t h y r o i d f u n c t i o n : t h e y in h i b i t t h e io d i d e u p t a k e o r g a n i f i c a t i o n , t h e y h i n d e r t h y r e o c y t e s g r o w t h , t h y r e o g l o b u l i n s y n t h e s i s a n d t h e r e l e a s e o f t h y r o i d h o r m o n e s , h e p a t i c d e i o n i z a t i o n w h i c h in t u r n a c t i v a t e s T 4 t o T 3
◦ I L - 1 β a n d T N F - αi n h i b i t T R H ,
P
N
E
I
PNEI
P S Y C HE
S O MA
P S Y C HE
P. N. E. I. NETWORK AND MES S ENG ER MOLECULES
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
I N T E R L E U K IN S
H O R M O N ES
N E U R O P E P T ID E S
H O R M O N ES
M e s s e n g e r M o l e c u l e s
T h e F o u n d a t i o n f o r P R MC O M M UN I C AT I N G
M O L E C UL E S a r e m e s s e n g e r s , t h e wo r d s
u s e d b y t h e 3 h o m e o s t a t i c c o n t r o l
s y s t e m s t o s p e a k e a c h o t h e r … a n d t o
u n d e r s t a n d e a c h o t h e r .© D i p a r t i m e n t o S c i e n t i f i c o
G u n a S . p . a .
53
EVERY D IS EAS E IS THE
EXPRES S ION, THE CONS EQUENCE
OF CHANG ED CONCENTRATION
OF MES S ENG ER MOLECULES
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
54
P. N. E. I. NETWORK AND MES S ENG ER MOLECULES
P
N
E
I
PNEI
P S YC HE
S O MA
P S YC HE
M O S C HU SN U X VO M I C A
N E U R O P E P T I D E S
HO R M O N E S
IN T E R L E U KI N S
THE P. N. E. I. NETWORK
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
P
N
E
I
PNEI
P S YC HE
S O MA
P S YC HE
THE P. N. E. I. NETWORK
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
IN T E R L E UKIN S
HO R M O N ES
N E U R O P E P TID E S
HO R M O N ES
H E A L T H
P HYS I O L O G I C A L C O N C E N T R A T I O N
D I S E A S E
D I S E A S EHYP O - C O N C E N T R A T I O N
HYP E R - C O N C E N T R A T I O N1 0- 6
1 0-1 5
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
4C – X6
g (gr a m )= 1
10 -1 = 0.1
10 -2 = 0.01
m g (m i lli gr a m )= 10 -3 = 0.001
μg (m i c r o gr a m )= 10 -6 = 0.000001
n g (n a n o gr a m )= 10 -9 = 0.000000001
p c g (p i c o gr a m )= 10 -12 = 0. 000000000001
f g (f e n t o gr a m )= 10 -15 = 0. 000000000000001
D E F I N I T I O N S
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
P h y s i o l o g i c a l R e g u l a t i n g M e d i c i n e
P R MP R M c o d i f i e s t h e v i s i o n
o f t h e p h y s i o l o g i c m i l i e u o f t h e o r g a n i s m
a s a p s y c h o - n e u r o -e n d o c r i n e - i m m u n e
N E T W O R K r e g u l a t e d b y m e c h a n i s m s o f F I N E C O N T R O L ( s e n s i t i v e l i g a n d -r e c e p t o r c o n t r o l
m e c h a n i s m s )© D i p a r t i m e n t o S c i e n t i f i c o
G u n a S . p . a .
59
P h y s i o l o g i c a l R e g u l a t i n g M e d i c i n e :
… a d y n a m i c n e w c o n c e p t
P R M m o v e s f r o m c l a s s i c a l Ho m e o p a t h y t o
t h e r e v o l u t i o n a r y t h e r a p e u t i c c o n c e p t o f
r e s t o r i n g p h y s i o l o g y t h r o u g h a d m i n i s t r a t i o n
o f c o m m u n i c a t i n g m o l e c u l e s - h o r m o n e s ,
i n t e r l e u ki n s , n e u r o p e p t i d e s a n d
g r o wt h f a c t o r s -p r e p a r e d i n
6 0© D i p a r t i m e n t o S c i e n t i f i c o
G u n a S . p . a .
P h y s i o l o g i c a l R e g u l a t i n g M e d i c i n e
P R MT h e h o m e o p a t h i c
p r e p a r a t i o n m e t h o d o f “d i l u t i o n - d y n a m i za t i o n ”
m a ke s t h e s e c o m m u n i c a t i n g
m o l e c u l e s e v e n m o r e e f f e c t i v e .
6 1© D i p a r t i m e n t o S c i e n t i f i c o
G u n a S . p . a .
6 2
TM
10 -3
1 0- 6
1 0-1 5
M I N I M A L E F F E C T I VE P HA R M A C O L O G I C A L D O S E
T O XI C CO N CE N T R A T I O
Nm g / m lP H A R M A CO L O G I CA L
CO N CE N T R A T I O Nm c g / m l
P HYS I O L O G I C A L C O N C E N T R A T I O N
ng- pcg/ml
T O XI C E F F E CT
S I D E E F F E CT S
WIT HO U T D YN A M I ZA T
IO N : N O BIO L O G I C A
LO r
P HYS I O L O G IC A L
E F F E C T S
P H A R M A CO L OG I CA L E F F E CT S
WIT H D YN A M I ZA T
IO N : P HYS I O L O G I
C A L E F F E C T S
E F F E C T S O F D I F F E R E N T D O S E S O F C YT O KI N E S
M I N I M A L E F F E C T I VE P HYS I O L O G I C A L D O S E
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
DYN AM I ZAT I O N =S.K .A.
S. Se qu e n t i a l
K . K i n e t i c
A. Ac t i v a t i o n© D i p a r t i m e n t o S c i e n t i f i c o
G u n a S . p . a .
• Hypothalamus–S o m a t o s t a t i n e–Be t a -
E n d o r p h i n• Hypophysis
–F S H–L H–A CT H–P r o l a c t i n–T S H
• P ineal G land–M e l a t o n i n
• T hyroid–T S H–T r i i o d o h y r o
n i n e ( T 3 )–T h y r o x i n e
( T 4)–Ca l c i t o n i n
• P arathyroids–P a r a t h o r m o
n e ( P T H )• O vary
–Be t a -E s t r a d i o l
–P r o g e s t e r o ne
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
Neuropeptides of PRM• H y I p o t h a l a m u s e
H y p o p h y s i s– Be t a - E n d o r f i n
• N u c l e u s o f r a f e o f B u l b o , o f B r i d g e a n d o f M e s e n c e f a l o . S t o m a c h a n d b o w e l– S e r o t o n i n
• P i n e a l G l a n d– M e l a t o n i n
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
6 66 6
E ffects of different doses of I L -1 - β on isolated human fibroblasts
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
in c o o p e r a t i o n wit h:
6 8© D i p a r t i m e n t o S c i e n t i f i c o
G u n a S . p . a .
E xpression of N F Kb and c- fos on isolated
fibroblasts
c - f o s
1 h 1 8h
lp s a c d b
1 h
n f k blp s a c
1 8h
lp s a c d b lp s a c d b
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
E xpression of N F Kb and c-fos on isolated fibroblasts
Legend
• lps=control• A =placebo (water and alcohol)• B=pharmacological concentration• C =4C H diluted and dynamized• D =4C H only diluted but not dynamized
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
7171
T h1 T h2
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
T HE IM M U N E S YS T E M
7272
T h- 1 /T h- 2 BA L A N C E
I L - 4IL - 5
C rohn’sP soriasis
A sthmaA topy
I L - 1 2IF N - T h- 1
T h- 2
T h- 2
T h- 1
I L - 1 2IF N -
I L - 4IL - 5
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
Th2
Th1
…in A llergy
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
T h0
T h2
T h1
IN F - γ, I L -1 2
I L - 4
IN H I BI TS
S T I M U LA T E S
S T I M U LA T E S
IN H I BI TS
I L -1 2
IN F- γ
THE CONCEPT OF BALANCED eveloping Th subsets results in cross -regulation. While I L - 4stimulates Th2 differentiation and inhibits diffentiation of Th 1cells, I L - 1 2 and I F N - γ stimulates Th 1 differentiation andinhibits the development of T h2 cells.
Cooke , A. Th17 in Inflammatory Conditions. 2006, Rev Diabetic Stud 3: 72-7- Bettelli E. et al. Th17: The third member of the effector T cell trilogy. Current Opinion in Immunology 2007, 19:
652-657
I L -4
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
7575
T h1I L - 1 2I F N -
T h2I L - 4IL - 5
A S T HM A
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
T he interleukins are able to rebalance the Immune S ystem in
A llergy
7676
T h1I L - 1 2IN F -
T h2I L - 4IL - 5
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
Healing from A sthma
7777
E ffects of low dose cytokines in treatment of inflammatory
pathologies: use in an animal model of allergic asthma
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
in c o o p e r a t i o n wit h:
E XP E R I M E N T A L P R O T O C O L
D A Y 1
In je c t i o n o f 1 m g o f e g g -a l b u m i n + 5 m g A l ( O H )3i n P BS ( I P )
D A Y 7
In je c t i o n o f 1 m g o f e g g -a l b u m i n + 5 m g A l ( O H )3i n P BS ( I P )
D A Y 1 3
A e r o s o l o f 1 m g o f e g g -a l b u m i n + 5 m g A l ( O H )3i n P BS
f r o m D A Y 1 8 u n t i l D A Y 3 8Blo o d d r a w i n g
T R E A T M E N T WIT H I L -1 2 +I F N - γ
L U C KY M O U S
E
A L L E RG I C
M O U S E
D A Y 2 7In je c t i o n o f 1 m g o f e g g -
a l b u m i n + 5 m g
D A Y 3 05% e g g -
a l b u m i n in P BS 0 ,5. ( A e r o s o l )
D A Y 38Bronchoalveolar
lavage fluid
0
10
20
30
40
50
60
[IL-
4] (
pcg/
ml)
0
20
40
60
80
1 00
[IL-
5] (
pcg/
ml)
1 20
1 40
1 60
1 80
U N T R O VA U N T R O VA
BA L F – after treatment with egg albumin and A l (O H)3
A sthma© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
T h2
T h1
Legend
• 1 - U ntr=healthy mouse• 2- O VA =allergic mouse
P rotocol G roups to test efficacy of treatment with 2 anti- allergic
interleukins in combination (I L -1 2+I F N - γ) in the allergic mouse
Legend• 1 - U ntr- - healthy mouse• 2- O VA - - allergic mouse• 3- O VA +A L L O - - I L - 1 2+I F N - γin pharmacological concentration• 4- O VA +4CH- - I L - 1 2+I F N - γ in physiological concentration (4CH) dilution and dynamized• 5- O VA +4CHn- - I L - 1 2+I F N - γ in physiological concentration (4CH) dilution © D i p a r t i m e n t o S c i e n t i f i c o
G u n a S . p . a .
Untr OVA OVA+Allo OVA+4CH OVA+4CHn OVA+30CH0
10
20
30
40
50
60
70
IL-4
pg/
ml
Untr OVA OVA+Allo OVA+4CH OVA+4CHn OVA+30CH0
20
40
60
80
100
120
140
160
180
IL-5
pg/
ml
L evel of I L - 4 and I L - 5 in mice sera
on day 7th of treatment
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
1 2 3 4 5
1 2 3 4 5
T reatment plan of allergic mouse with the 2 anti- allergic interleukines in association
(IL - 1 2+IF N - γ)
Legenda• 1 - U ntr=healthy mouse• 2- O VA =allergic mouse• 3- O VA +A L L O =IL - 1 2+IF N - γ in pharmacological concentration• 4- O VA +4CH=IL - 1 2+IF N - γ in physiological concentration (4CH) diluted and dinamized• 5- O VA +4CHn=IL - 1 2+IF N - γ in physiological concentration (4CH) only diluted but not dinamized
L evels of I L - 4
L evels of I L - 5
Untr OVA OVA+Allo OVA+4CH OVA+4CHn OVA+30CH0
500
1000
1500
2000
2500
IL-1
2 pg
/ml
Untr OVA OVA+Allo OVA+4CH OVA+4CHn OVA+30CH0
1000
2000
3000
4000
5000
6000
IFN
gam
ma
pg/m
l
L evel of I L - 1 2 and IN F - γin mice sera
on day 7th of treatment
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
1 2 3 4 5
1 2 3 4 5
T reatment plan of allergic mouse with the 2 anti- allergic interleukines in association
(IL - 1 2+IF N - γ)
Legenda
• 1 - U ntr=healthy mouse• 2- O VA =allergic mouse• 3- O VA +A L L O =IL - 1 2+IF N - γ in pharmacological concentration• 4- O VA +4CH=IL - 1 2+IF N - γ in physiological concentration (4CH) diluted and dinamized• 5- O VA +4CHn=IL - 1 2+IF N - γ in physiological concentration (4CH) only diluted but not dinamized
L evels of I L - 1 2
L evel of I F N - γ
p gp gf gf g
U nit of measurement……the mistery… that is not a
mistery
4CH
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
we give… …we detect in the blood
U N T R E A T E D 0
O V A =C O N T R O L ( A L L E R G I C M O U S E ) 2 0 , 1 88±0 , 6 1 3
OVA + A L L O ( P H A R M A C O L O G I C A L T R E A T M E N T ) 0
OVA + 4 C H ( 4 C H S K A - A C T IVIT E D T R E A T M E N T ) 0
O V A +4 C H n ( 4 C H n o t - SKA -A C T I V I T E D T R E A T M E N T ) 19,567±0 , 6 85
O V A +3 0 C H ( 3 0 C H SKA - A C T I V I T E D T R E A T M E N T ) 2 0 ,788±0 , 4 1 6
Number of cells expressed in cells/BALF (x1 04)
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
E osinophil numbers in mouse BA L F
(bronchoalveolar lavage fluid) on day 20 of treatment
IL-12
0,00
5,00
10,00
15,00
20,00
25,00
30,00
Untr OVA+100ng/die OVA+4CH din
[IL-1
2] (p
g/m
l)
05
101520253035404550
Untr OVA+100ng/die OVA+4CH din
[IFN
gam
ma]
(pg/
ml)
IFN-g
S afety of clinical use of S KA treated low doses of interleukines
P reliminary datas
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
PRM
ANTI AG ING THERAPIES
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
86
Ivo BIANCH I M.D. ©
E L D E R L Y P e o p l e
L o w R e a c t i v i t y
Ce l lS t i m u l a t i o n G U N A Ce l l
T i s s u eS t i m u l a t i o n G U N A M a t r i x
H o r m o n a lS t i m u l a t i o n
G U N A F e m a l e / M a l e
Im m u n e S t i m u l a t i o n Cit o m i x
H i g h L e v e l o fIn t o x i c a t i o n D r a i n a g e
G e n e r i c
S p e c i f i c
H i g h L e v e l o fIn f l a m m a t i o n
A n t i In f l a m m a t i o n
G U N A F l a m
IL - 1 0
• G U N A - F E M / M A L E : 2 0 d r o p s t w i c e a d a y fo r 2 - 4 m o n t h s
+G U N A - F L A M : 2 0 d r o p s t w i c e a d a yfo r 2 - 4 m o n t h s
• M E L A T O N I N 4 C H : 2 0 d r o p s a t e v e n i n ge v e r y d a y fo r 2 - 4 m o n t h s
+• I G F 1 4 CH : 2 0 d r o p s a t e v e n i n g e v e r y d a y fo r2 - 4 m o n t h s (anti-neoplastic and anti-oxidant action)
• I L 2 4 CH : 2 0 d r o p st w i c e a d a y fo r 2 - 4 m o n t h s (it is the “amti-aginginterleukine)
• CE R E B R U M CO M P . : 1 a m p o u l e v r y 2 d a y s fo r 2 - 4 m o n t h s (elderly people)
• G U N A -G E R I A T R I CS : 2 0 d r o p s t w i c e a d a y f o r 2 - 4 m o n t h s
A N T I A G I N G G E N E R A L S T R A T E G Y
• G U N A - M A T R I X: 2 0 d r o p s t w i c e a d a y fo r 2 - 4 m o n t h s
+• G U N A - CE L L : 2 0 d r o p s t w i c e a d a y fo r 2 - 4 m o n t h s
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
88
T r o p h i ce f f e c t
A n t i a g i n g
Ca t a b o l i ce f f e c t
A n t i c a n c e r
M e l a t o n i n
T 3
S o m a t o s t a t i n
IG F - 1
D H E A
G H
I n a n i m a l s l o n g l i f e i s c o r r e l a t e d w i t h :
◦H i g h l e v e l s o f : I G F - 1M e l a t o n i n
Ma t r i x liqu i f i c a t i
o n a n d dr a i n a ge
Ac t i o n a ga i n st t o xi n im p r e gn a t i o
n Lym p ha t i
c dr a i n a ge
•S t i m u la t i o n o f m i t o c ho n dr i a l
e n e r gy p r o du c t i o n . *
•Ma t r i x a c i di f i c a t i o n (p r o m o t i n g
c o n n e c t i ve t i ssu e r e a c t i vi t y). **
•Ac. D-L malicum 6X*•Natrium oxal. 6X*
•Natrium pyruv. 6X*•NADID 6X*
•Trychinoil 6X*•Vit. C 2X*
•Ac. L(+) lacticum3X**•D e a c t i va t i o n (thr o u gh in f la m m a t i o n ) a n d n e u t r a li za t i o n o f t he im p r e gn a t e d t o xi n s*.
•S yn e r gi st i c a c t i o n wit h Fu c u s a n d t hyr o i d ho r m o n e a c t i va t i n g the sym p a t he t i c o t o n i c n e r vo u s syste m **.
•Pyrogenium 12X*•Fucus 3X*
•Tyrosine 2X**•Phenilalanine 2X**
•Histidine 2X**
•In a c t i ve t o xi n s m o bi li ze d t o wa r ds t he lym p ha t i c c i r c le f o r dr a i n a ge
•Lymphatic vessel 6X
•Ma t r i x hydr o lysi s*
•Ac t i o n a ga i n st t he c o n st i t u t i o n a l t e n de n c y t o im p r e gn a t i o n o f t he m a t r i x wit h t o xi n s a n d t o t he de ve lo p m e n t o f Dysmetabolic Mesenchymopathy (psychcosis).**
•Ma t r i x
•Hyaluronidase 6X*•Thuja 6/8/12/30/200X**
•Natrium sulfuricum 6/8/12/30/200X **•Prolactine 6X***
•DHEA 6X***•In c r e a se o f Fu n da m e n t a l S u bst a n c e kin e t i c s (p r o t e i n hydr o lysi s, hyp e r -i o n i c i t y, hist a m i n i c a c t i vi t y, in c r e a se d t e m p e r a t u r e ) a n d m a t r i x t u r n o ve r r a t e . *
•S ym p a t he t i c o t o n i c
•IL 6 4C*•DHEA 6X*
•Pyrogenium 12X*•Conjunctive Tissue 6X*
•Tyrosine 2X**•Phenilalanine 2X**
•Histidine 2X**•Prolactine 6X***
G UNA-MATRIX
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
91
• Mo du la t i o n o f t he n e u r o ge n i c p ha se o f in f la m m a t i o n *.
• S e n si t i za t i o n o f the be t a -e n do r p hi n p e r i p he r a l r e c e p t o r s**.
• RES st i m u la t i o n a n d hin dr a n c e t o t he p o ssi ble se p t i c p r o gr e ssi o n o f the in f la m m a t o r y p r o c e ss.
The 3 p i lla r s… i n a dr u g
G UNA-FLAM
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
Ac o n i t u m *Be lla do n n a *
Fe r r u m p ho sp ho r i c u m *Ap i s*
Br yo n i a *Pyr o ge n i u m *Phyt o la c c a *
Na t r i u m p yr u vi c u m *Ac i du m c i t r i c u m *
Cu -glu c o n a t e *An t i IL 1-a lf a **TG F 1 be t a ***
IL 10***
• Mo du la t i o n o f the n e u r o ge n i c , va sa l e xu da t i ve p ha se s o f the in f la m m a t o r y p r o c e ss*.
• Hin dr a n c e t o the in f la m m a t i o n st a r t p o i n t **.
• Po t e n t i a t i o n o f t he im m u n o lo gi c a n t i -in f la m m a t o r y a c t i vi t y ha vi n g Th2-Th3 p o la r i t y***.
Ac o n i t u m *Be t a -e n do r p hi n **
He p a r su lf u r i sPyr o ge n i u m
Fe r r u m p ho sp ho r i c u m
Me la t o n i n 4CHyp o p hysi s p o r c i n e 200X
Pin e a l G la n d 6XCo n ju n c t i ve t i ssu e 12X
• Re gu la t i o n o f t he e xt r a c e llu la r m a t r i x fu n c t i o n t hr o u gh t he m o du la t i o n o f t he hyp o p hysa r y ho r m o n s a c t i o n a n d the p i n e a l gla n d st i m u la t i o n .
G UNA CELL
Vit a m i n s
In c r e a se o f e n e r ge t i c m e t a bo li sm .
Co e n zym e a c t i vi t y p e r f o r m i n g c a t a lyt i c a c t i o n o n c e ll f u n c t i o n s.
Ca t a lyt i c a c t i o n o n e n zym e f u n c t i o n s.
• Ca r r i e r a c t i o n *.
• Re p r o gr a m m i n g o f c e ll f u n c t i o n **.
• 2n d f u n c t i o n m e sse n ge r ***.
-lip o i c -a c . 3X
S u c c i n i c . a c . 3X
Fu m a r i c . a c . 3X
Me t hyglyo xa l 10X
Vit . EVi t . C
Vit . B1, B2, B3, B5, B6, B9, B12
Co lc hi c u m 6/12/30X Co n i u m 6/12/30X
Po do p hyllu m 6/12/30XMe t hyglyo xa l 10X
An t i -de ge n e r a t i ve a n d a n t i -a gi n g a c t i o n .
Ac . -L-c a r n i t i n e * 2X D NA** 6X RNA** 6X
Co lli n so n i a 2X*** c AMP 6X*** Mn -glu c . 3X
Mn -p ho sp h. 6XMg-p ho sp h. 3X
P 4XCa -glu c . 3X
Fe f u m a r . 3XS 3X
S e 3XCu su lp h. 3XZn -glu c . 3X
K-a sp a r t . 3X
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
93
D6D3
S u i s -O r g a n s
10 pg
NT3 NT4 Melatonin
H o r m o n e sN e u r o t r o p h i n s
Plumbummetallicum
Hepar
Lobofrontalis
Glandulasuprarenalis
HypothalamusBarytacarbonica
H o m e o p a t h i cR e m e d i e s
Phenilalanine
Thyrosine
Oxitocine
TRH
LH-RH
ACTH AcidumDL-malicum
Catalysts
Acidumpyruvicum
H o r m o n e s
BDNF
Parabenzochinon
Baryumoxalsuccinicum
Arnica
IGF-1
A minoacids
H e r b a l s(A r n i c a
m o n t a n a )
H e r b a l s(A r n i c a
m o n t a n a )Ca t a l ys ts a n d
a m i n o ac i d s
Ca t a l ys ts a n d
a m i n o ac i d sG r o w t h
f a c t o r s G r o w t hf a c t o r s
H o r m o n e sH o r m o n e sCo u r t e s y fr o m D r . I Bia n c h i
Co u r t e s y fr o m D r . I Bia n c h i
M e l a t o n i nIn s u l i nG r o w i nF a c t o r
A CT H
Co u r t e s y fr o m D r . I Bia n c h i
O x i t o c i n e T R H L H - R H
Co u r t e s y fr o m D r . I Bia n c h i
• Cir c u l a t i n g m e l a t o n i n d e c r e a s e s w i t h a g e a n d in r e c e n t ye a r s m u c h in t e r e s t h a s b e e n f o c u s e d o n i t s im m u n o m o d u l a t o r y e f f e c t .
• M e l a t o n i n s t i m u l a t e s t h e p r o d u c t i o n o f p r o g e n i t o r c e l l s f o r g r a n u l o c yt e s -m a c r o p h a g e s . I t a l s o s t i m u l a t e s t h e p r o d u c t i o n o f N K c e l l s a n d CD 4+ c e l l s a n d in h i b i t s CD 8+ c e l l s .
• T h e p r o d u c t i o n a n d r e l e a s e o f v a r i o u s c yt o k i n e s f r o m N K c e l l s a n d T - h e l p e r lym p h o c yt e s a l s o a r e e n h a n c e d b y m e l a t o n i n .
• M e l a t o n i n p r e s u m a b l y r e g u l a t e s im m u n e f u n c t i o n b y a c t i n g o n t h e im m u n e -o p i o i d n e t w o r k , b y a f f e c t i n g G p r o t e i n - c A M P s i g n a l
M e l a t o n i n h a s t h e p o t e n t i a l t h e r a p e u t i c v a l u e t o e n h a n c e im m u n e f u n c t i o n in a g e d in d i v i d u a l s a n d in p a t i e n t s in a n im m u n o c o m p r o m
Co u r t e s y fr o m D r . I Bia n c h i
Insulin- like growth factors ( I G F s ) a r e p o l i p e p t i d e s w i t h h i g h s e qu e n c e s i m i l a r i t y t o in s u l i n
IG F - 1 i s m a i n l y s e c r e t e d b y t h e l i v e r a s a r e s u l t o f s t i m u l a t i o n b y G H .
IG F - 1 i s im p o r t a n t f o r b o t h t h e r e g u l a t i o n o f n o r m a l p h ys i o l o g y, a s w e l l a s a n u m b e r o f p a t h o l o g i c a l s t a t e s , in c l u d i n g c a n c e r
IG F a x i s h a s b e e n s h o w n t o p l a y r o l e s in t h e p r o m o t i o n o f c e l l p r o l i f e r a t i o n a n d in h i b i t i o n o f a p o p t o s i s
F a c t o r s t h a t a r e k n o w n t o c a u s e v a r i a t i o n in t h e le v e l s IG F - 1 in t h e c i r c u l a t i o n in c l u d e a n in d i v i d u a l s
Co u r t e s y fr o m D r . I Bia n c h i
I t w a s d e m o n s t r a t e d t h a t a d m i n i s t r a t i o n o f A CT H l e d t o f a c i l i t a t i o n o f l e a r n i n g a n d s t r e n g t h e n i n g o f m e m o r y p r o c e s s e s ( c o n d i t i o n e d r e f l e x t r a c e s ). A CT H p r o m o t e d s t r e n g t h e n i n g o f m o v e m e n t , o r i e n t a t i o n a l - i n v e s t i g a t i v e , a n d in t e r s i g n a l a c t i v i t i e s , p r o d u c e d h yp e r a l g e s i a , a n d b l o c k e d t h e e f f e c t s o f n a l o x o n e
A CT H i s i n v o l v e d in m o t i v a t i o n , Co u r t e s y fr o m D r . I Bia n c h i
O x yt o c i n i s a m a m m a l i a n h o r m o n e t h a t a l s o a c t s a s a n e u r o t r a n s m i t t e r in t h e b r a i n .
O x yt o c i n i s r e l e a s e d d u r i n g o r g a s m in b o t h s e x e s .
I n t h e b r a i n , o x yt o c i n i s in v o l v e d in s o c i a l r e c o g n i t i o n a n d b o n d i n g , a n d m i g h t b e in v o l v e d in t h e f o r m a t i o n o f t r u s t b e t w e e n p e o p l e , i n g e n e r o s i t y a n d in t h e r e d u c t i o n o f f e a r
Ca n im p a i r m e m o r y r e t r i e v a l in c e r t a i n a v e r s i v e m e m o r y t a s k s .
Co u r t e s y fr o m D r . I Bia n c h i
T h e b r a i n t r i p e p t i d e t h yr o t r o p i n - r e l e a s i n g h o r m o n e ( T R H ) h a s b e e n d e m o n s t r a t e d t o f a c i l i t a t e c h o l i n e r g i c n e u r o t r a n s m i s s i o n .
T R H m a r k e d l y a t t e n u a t e d s c o p o l a m i n e - i n d u c e d im p a i r m e n t o f s o m e m e a s u r e s o f m e m o r y, m o s t n o t a b l y o n a s e l e c t i v e r e m i n d i n g t a s k .
Cognitive study suggest a facilitatory role for T R H in human memory processes.
S cientific studies suggest that stimulation of T R H may be useful for
Co u r t e s y fr o m D r . I Bia n c h i
N e u r o t r o p h i c f a c t o r s a r e e n d o g e n o u s p r o t e i n s t h a t a l t e r t h e s u r v i v a l , d e v e l o p m e n t , m a i n t e n a n c e , a n d d i f f e r e n t i a t i o n o f n e u r o n s .
E v i d e n c e h a s in d i c a t e d t h a t n e u r o t r o p h i c f a c t o r s m a y b e im p l i c a t e d in t h e n o r m a l f u n c t i o n a l a c t i v i t y o f n e r v e c e l l s .
T h e s e m o l e c u l e s a r e g e n e r a l l y s m a l l , s o l u b l e p r o t e i n s w i t h
Co u r t e s y fr o m D r . I Bia n c h i
N erve G rowth F actor (N G F ) T h e f i r s t k n o w n n e u r o t r o p h i n , a c t s p r e d o m i n a n t l y o n s ym p a t h e t i c a n d s e n s o r y n e u r o n s .
Brain D erived N eurotrophic F actor (BD N F ) S u p p o r t s m o t o n e u r o n d e v e l o p m e n t a n d s u r v i v a l in a n i m a l s a n d p r e v e n t s n a t u r a l l y o c c u r r i n g d e a t h
N eurotrophin 3 (N T - 3) N T - 3 is r e l a t e d t o N G F a n d h a s h o m o l o g y w i t h i t . I t i s f o u n d in m o t o r n e u r o n s , s ym p a t h e t i c n e u r o n s a n d s o m e p e r i p h e r a l s e n s o r y
Co u r t e s y fr o m D r . I Bia n c h i
• A c t i n g o n c e r t a i n CN S n e u r o n s a n d o n t h e p e r i p h e r a l n e r v o u s s ys t e m
• H e l p s t o s u p p o r t t h e s u r v i v a l o f e x i s t i n g n e u r o n s a n d e n c o u r a g e t h e g r o w t h a n d d i f f e r e n t i a t i o n o f n e w n e u r o n s a n d s yn a p s e s
• A c t i v e in t h e H yp p o c a m p u s , Co r t e x , Ba s a l F o r e b r a i n a r e a s v i t a l t o le a r n i n g , m e m o r y, a n d h i g h e r t h i n k i n g .
• A l t h o u g h t h e v a s t m a jo r i t y o f n e u r o n s in t h e b r a i n a r e f o r m e d p r e n a t a l l y, p a r t s o f t h e a d u l t b r a i n r e t a i n t h e a b i l i t y t o g r o w n e w n e u r o n s f r o m n e u r a l s t e m
Co u r t e s y fr o m D r . I Bia n c h i
BD N F is o n e o f t h e m o s t a c t i v e n e u r o t r o p h i n s . M i c e b o r n w i t h o u t t h e a b i l i t y t o m a k e BD N F s u f f e r d e v e l o p m e n t a l d e f e c t s in t h e b r a i n a n d s e n s o r y n e r v o u s s ys t e m , a n d u s u a l l y d i e s o o n a f t e r b i r t h , s u g g e s t i n g t h a t BD N F p l a ys a n im p o r t a n t r o l e in n o r m a l n e u r a l d e v e l o p m e n t
BD N F is a c t u a l l y f o u n d n o t o n l y in t h e b r a i n b u t a l s o in a r a n g e o f t i s s u e a n d c e l l t yp e s : R e t i n a , M o t o r n e u r o n s , Kid n e ys a n d P r o s t a t e .
V a r i o u s s t u d i e s h a v e s h o w n p o s s i b l e l i n k s b e t w e e n lo w le v e l s o f BD N F a n d c o n d i t i o n s s u c h a s : D e p r e s s i o n , S c h i zo f r e n i a ,
Co u r t e s y fr o m D r . I Bia n c h i
N eurotrophin- 3 (N T - 3) s u p p o r t s t h e s u r v i v a l a n d d i f f e r e n t i a t i o n o f n e u r o n e s in t h e c e n t r a l a n d p e r i p h e r a l n e r v o u s s ys t e m s t h r o u g h a n u m b e r o f m e c h a n i s m s t h a t o c c u r in a m a t t e r o f h o u r s o r d a ys . N T - 3 m a y a l s o h a v e a m o r e r a p i d m o d e o f a c t i o n t h a t in f l u e n c e s s yn a p t i c a c t i v i t y in m a t u r e n e u r o n e s . N T - 3 , h a v e b e e n im p l i c a t e d in t h e r e g u l a t i o n o f s yn a p t i c t r a n s m i s s i o n a n d p l a s t i c i t y.
Co u r t e s y fr o m D r . I Bia n c h i
I n c r e a s i n g a m o u n t s o f e v i d e n c e in d i c a t e t h a t i n f l a m m a t o r y p r o c e s s e s a r e in v o l v e d in t h e n e u r o t o x i c i t y o f A D . A c e n t r a l e v e n t in t h e s e p r o c e s s e s a p p e a r s t o b e t h e a c t i v a t i o n o f m i c r o g l i a b y a v a r i e t y o f f a c t o r s , in c l u d i n g b a m yl o i d a n d p r o i n f l a m m a t o r y c yt o k i n e s .
A c t i v a t e d m i c r o g l i a in t u r n r e l e a s e p r o i n f l a m m a t o r y c yt o k i n e s , s u c h a s I L - 1 - b, I L - 6 , a n d T N F - a, t h a t m a y le a d t o n e u r o n a l d e a t h a n d d ys f u n c t i o n b y a v a r i e t y o f m e c h a n i s m s , in c l u d i n g ◦ e n h a n c e m e n t o f g l u t a m a t e - i n d u c e d
e x c i t o t o x i c i t y[
◦ in h i b i t i o n o f lo n g - t e r m p o t e n t i a t i o n , w h i c h l i m i t s f u n c t i o n a l p l a s t i c i t y a f t e r n e u r o n a l in ju r y[
Co u r t e s y fr o m D r . I Bia n c h i
D E M E N T I A
A l zh e i m e r ’s D i s e a s e s
U p r e g u l a t e d .:IL - 6
IL - 1 0T N F
D o w n r e g u l a t e d.: IL - 2
V a s c u l a rD e m e n t i a
U p r e g u l a t e d .:IL - 6
IL - 1 0IL - 1 b
D o w n r e g u l a t e d.: IL - 2
Co u r t e s y fr o m D r . I Bia n c h i
T h yr o x i n e F e n i l a l a n i l n e
Co u r t e s y fr o m D r . I Bia n c h i
N o n e s s e n t i a l a m i n o a c i d s yn t h e s i ze d in t h e b o d y f r o m p h e n yl a l a n i n e . A s a b u i l d i n g b l o c k f o r s e v e r a l im p o r t a n t b r a i n c h e m i c a l s , t yr o s i n e is n e e d e d t o m a k e e p i n e p h r i n e , n o r e p i n e p h r i n e , s e r o t o n i n , a n d d o p a m i n e , a l l o f w h i c h w o r k t o r e g u l a t e m o o d .
D e f i c i e n c i e s in t h i s a m i n o a c i d is a s s o c i a t e d w i t h d e p r e s s i o n .
T yr o s i n e a l s o a i d s in t h e p r o d u c t i o n o f m e l a n i n a n d in t h e f u n c t i o n o f t h e a d r e n a l , t h yr o i d , a n d p i t u i t a r y g l a n d s . T yr o s i n e is a l s o in v o l v e d in t h e s yn t h e s i s o f e n k e p h a l i n s , s u b s t a n c e s t h a t h a v e p a i n - r e l i e v i n g e f f e c t s in t h e b o d y.
L o w le v e l s o f t yr o s i n e h a v e b e e n a s s o c i a t e d w i t h lo w b l o o d p r e s s u r e , lo w b o d y t e m p e r a t u r e , a n d a n u n d e r a c t i v e t h yr o i d . Be c a u s e t yr o s i n e b i n d s u n s t a b l e m o l e c u l e s ( c a l l e d
Co u r t e s y fr o m D r . I Bia n c h i
H e p a r s u i s• S u p p o r t o f D i g e s t i v e a n d D e t o x i c a t o r y
F u n c t i o n s
S u p r a r e n a l s u i s• O p p o s i n g A g e a n d S t r e s s R e l a t e d
E n d o c r i n e d i s f u n c t i o n s
H yp o t h a l a m u s s u i s• R e s e t t i n g o f b i o l o g i c a l c l o c k
L o b u s f r o n t a l i s s u i s• A n t a g o n i zi n g Co g n i t i v e d e t e r i o r a t i o n
Co u r t e s y fr o m D r . I Bia n c h i
A p p l i c a t i o n o f
c yt o k i n e s m o d e l i n A u t o i m m u n e
D i s e a s e s a n d M u s c l e - S k e l e t i c a l P a i n M a n a g e m e n t
A p p l i c a t i o n o f a n t a g o n o s t i c
l o w d o s e S KA -a c t i v e t e d
c yt o k i n e s m o d e l i n A u t o i m m u n e
D i s e a s e s a n d M u s c l e - S k e l e t i c a l P a i n M a n a g e m e n t
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
1 1 61 1 6
I nflammationCytokines
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
I N F L A M M A T I O N
A N T I - I nflammationCytokines
I L - 1T N F - α
6
• I L - 1• T N F - α• I L - 6
A nti- I L -
1 0
• A nti- I L -• I L - 4• I L - 1 0
Interleukin 1 (I L - 1 ) cytokine secreted by macrophages, monocytes, dendritic cells, fibroblasts and endothelial cells• I L - 1 support inflammatoryprocesses
• Stimulates prostaglandinsproduction
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
INTERLEUKINE-1 (α; ß)
I L - 1
IN F L A M M A T I O NS YN O VI A L P A N N U S
F O R M A T I O N
CA R T I L A G E BR E A KD O WN S
BO N E R E S O R P T I O N
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
IL-1 (α; ß) ACTION MECHANISM
I L - 1 (α; ß) a c t i v a t e :1 . cyclooxygenase type 2(CO X2)2.prostaglandin E 2 (P G E 2)3.nitric oxide (N O )
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
CONVENTIONAL DRUGS TO STOP INTERLEUKINE-1 EFFECTS
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
N S A ID s
CO R TI S O N
A S A
- - -CO X2 P G E 2 N O
Low dose SKA-actived Antibody AntiInterleukins -1 (α and β) in Pain
Management
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
A nti I L - 1
I L-1
CO X2
P GE 2
N O
-BL O CK
A ntiI n t e r l e u k i n s - 1 (α; ß) act a s N S A I D s (A ), cortisone (B) and, in part, as salicylates (C), w i t h o u t t h e n e g a t i v e s i d e e f f e c t s c a u s e d
T HE R A P E U T I C A P P R O A CH WIT HL O W D O S E S .K.A . A N T I BO D Y A N T I I L - 1 , I L - 4 & I L - 1 0 IN
M U S CL E - S KE L E T A L P A I N M A N A G E M E N T
• A nti I L - 1 4CH D ecrease of acute inflammation.
• I L - 1 0 4CH D ecrease of chronic inflammation.
• I L - 4 4CH Control of autoimmune © D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
• Cytokines are effective
• However pharmacological doses is plagued with severe adverse effects
U nless…1. Marinaro, M. et al. 1999. Use of intransal IL-12 to target predominantly
Th1 responses to nasal and Th2 resposnses to oral vaccines given with cholera toxin. J. Immunol. 162(1): 114-121
2. Mariinaro, M. et al. 1997. Oral but not parenteral interleukin IL-12 redirects T helper 2 (Th2)-type resposnses to an orola vaccine without
altering mucosal IgA responses. J. Exp. Med. 185(3): 415-4273. Lee, S. Y. et al. 2001. Oral administration of IL-12 suppresses
anaphylatctic reactions in a murine model of peanut hypersensitivity. Clin. Immunol. 101(2): 220-228
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
END ORPHIN
En do r p hi n s a r e o r g a n i c c he mi c a l s ubs t a n c e s p r o duc e d by t he CNS, ha vi n g a n t i p a i n a n d p hys i o l o g i c a l c ha r a c t e r i s t i c s s imi l a r t o t ho s e o f morphine a n d opium – ho we ve r t he y ha ve a wide r r a n g e
En do r p hi n s , l i ke a n umbe r o f mo r p hi n i c o r i g i n a l ka l o i ds , c a n c a us e s t a t e s o f e up ho r i a a n d s o mn o l e n c e a c c o r di n g t o t he qua n t i t y r e l e a s e d
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
PRM: What is derived from Homeopathy?
The study of the pharmacological effects of homeopathized
PLANT, MINERALS and ANIMAL COMPONENTS on
healthy humans and their usage depending on the principles
of similarity and effect inversion in an ill subject.
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
1 25
• Ac o n i t i n 10-5 M Fi br i lla t i o n
• Ac o n i t i n 10-7 M Br a dyc a r di a
• Ac o n i t i n 10-18 M No e ffe c to n he a l t hy he a r t
Ryt hm
A conitin experimentation Pennec, J.P., Aubin, M (1984) – Effect of Aconitum and Veratrum on the isolated and perfused heart of the common eel. Comp. Biochem,
Physiol. 776:367.Diffe r e n t e ffe c t s o f Ac o n i t i n c o n c e n t r a t i o n s o n is o l a t e d a n d p e r fus e d e e l he a r t :
X5
X7
X1 8
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
0
5000
10000
15000
20000
25000
35S
-cp
m/1
00g
SM
PS Co n t r o l
5 mg c o r t i s o n e
0.5 mg c o r t i s o n e
0.0005 mg c o r t i s o n e
0.00005 mg c o r t i s o n e
0.000005 mg c o r t i s o n e
H a us s Exp e r ime n t a t i o n (1968)S T U D I E S O N T HE "N O N S P E CI F I C M E S E N CHYM A L R E A CT I O N " A N D T HE “1
T R A N S I T ZO N E " IN M YO CA R D I A L L E S I O N S A N D A T HE R O S CL E R O S I S W. H . H a u s s , U . G e r l a c h , G . Ju n g e - H ül s i n g , H . T h e m a n n W. Wir t h
A n n a l s o f th e N e w Y o r k A c a d e m y o f S c i e n c e s , V o l u m e 1 56 , E x p e r i m e n t a l "M e t a b o l i c " Ca r d i o p a t h e s a n d th e i r R e l a t i o n s h i p t o H i m a H e a r t D i s e a s e ,
P a g e 20 7- 21 8, Ja n 1 96 9, d o i : 1 0 . 1 1 1 1 / j. 1 749- 6 6 3 2. 1 96 9. t b 1 6 729. xEffe c t s o f va r yi n g g luc o c o r t i c o i d c o n c e n t r a t i o n s o n
me s e n c hyma l s ys t e m t ur n -o ve r
(c o n n e c t i ve t i s s ue bio l o g i c a l a c t i vi t y)
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
High doseS t r yc n
o s N u x
v o m i ca
+ + + +
Increased excitability of parasympathetic fibers
p a r a s ym p a t he t i c f i b e r
a c e t yl c h o l i ne
A c e t yl c h o l i n e r e c e p t o r
P a r i e t a l c e l l o f g a s t r i c m u c o s a
p r o to n
p o mp
+
H Cl ( h yd r o c h l o r ic a c i d )
+
E ffects of high dose S trycnos N ux vomica on acetylcholine receptors of
gastric mucosa parietal cells
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
Homeopathic dose
S t r yc n os N u x
v o m i c a
- - --
p r o to n
p o mp
-
-
E ffects of ho meo pa t hic do s e S trycnos N ux vomica on acetylcholine receptors of gastric mucosa parietal cells
D ecreased excitability of parasympathetic fiber
p a r a s ym p a t he t i c f i b e r
A c e t yl c h o l in e
A c e t yl c h o l i n e r e c e p t o r
P a r i e t a l c e l l o f g a s t r i c m u c o s a
H Cl ( h yd r o c h l o r ic a c i d )
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
• A R N I CA (Arnica montana)• A CO N I T U M (Aconitum napellus)• R HU S T O X. (Rhus toxicodendron)• CIM I CI F U G A (Cimicifuga racemosa)• VIO L A O D O R A T A • CA U L O P HYL L U M (Caulophyllum talictroides)• A CI D U M BE N ZO I CU M• L E D U M (Ledum palustre)• CO L O CYN T HI S (Citrullus colocynthis)
Important homeopatic single remedies for P ain M anagement:
• A CI D U M F O R M I CI CU M• G N A P HA L I U M P O L YCE P HA L U M• R HO D O D E N D R O N CHR YS A N T HU M• L A CHE S I S M U T U S• BR YO N I A A L BA• HYP E R I CU M P E R F O R A T U M• BE L L A D O N N A (Atropa belladonna)• CR O T A L U S HO R R I D U S• KA L M I A L A T I F O L I A• E T C.
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
• Mo du la t i o n o f t he n e u r o ge n i c p ha se o f in f la m m a t i o n *.
• S e n si t i za t i o n o f the be t a -e n do r p hi n p e r i p he r a l r e c e p t o r s**.
• RES (r e t i c u lo e n do t he lia l syste m ) st i m u la t i o n a n d in hi bi t i o n o f the p o ssi ble se p t i c p r o gr e ssi o n o f the in f la m m a t o r y p r o c e ss.
Ho m e o p a t hi c a n d Mo le c o la r Bio lo gy
r e m e di e s… in 1 dr u g
G UNA-FLAM
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
Ac o n i t u m *Be lla do n n a *
Fe r r u m p ho sp ho r i c u m *Ap i s*
Br yo n i a *Pyr o ge n i u m *
Phyt o la c c a *Na t r i u m p yr u vi c u m *
Ac i du m c i t r i c u m *Cu -glu c o n a t e *An t i IL 1-a lf a **TG F 1 be t a ***
IL 10***
• Mo du la t i o n o f the n e u r o ge n i c , va sc u la r e xu da t i ve p ha se s o f t he in f la m m a t o r y p r o c e ss*.
• In hi bi t i o n o f t he in f la m m a t o r y c a sc a de st a r t i n g p o i n t **.
• Po t e n t i a t i o n o f im m u n o lo gi c a n t i -in f la m m a t o r y a c t i vi t y ha vi n g Th2-Th3 p o la r i t y***.
Ac o n i t u m *Be t a -e n do r p hi n **
He p a r su lf u r i sPyr o ge n i u m
Fe r r u m p ho sp ho r i c u m
Me la t o n i n 4CHyp o p hysi s p o r c i n e 200X
Pin e a l G la n d 6XCo n ju n c t i va t i ssu e 12X
• Re gu la t i o n o f ECM (e xt r a c e llu la r m a t r i x) f u n c t i o n t hr o u gh m o du la t i o n o f hyp o p hyse a l ho r m o n e a c t i o n a n d p i n e a l gla n d st i m u la t i o n
S U P P O R T I VE O R A L T HE R A P Y IN
P A I N M A N A G E M E N T
Directions• G U N A - F L A M : 20 d r o p s t w i c e a d a y f o r a t
l e a s t 1 m o n t h
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
MATRIX
MEMBRANE RECEPTORS
VESSELS
THE
CON
NEC
TIVE
TIS
SUE
Mo
rpho
-fun
cti
on
al
unit
y: v
es
se
l-m
atr
ix-m
em
bra
ne
re
ce
pto
r
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
Ma t r i x liqu i f i c a t i
o n a n d dr a i n a ge
Ac t i o n a ga i n st t o xi n im p r e gn a t i o
n Lym p ha t i
c dr a i n a ge
•S t i m u la t i o n o f m i t o c ho n dr i a l
e n e r gy p r o du c t i o n . *
•Ma t r i x a c i di f i c a t i o n (p r o m o t i n g
c o n n e c t i ve t i ssu e r e a c t i vi t y). **
•S t i m u la t i o n o f m i t o c ho n dr i a l
e n e r gy p r o du c t i o n . *
•Ma t r i x a c i di f i c a t i o n (p r o m o t i n g
c o n n e c t i ve t i ssu e r e a c t i vi t y). **
•Ac. D-L malicum 6X*•Natrium oxal. 6X*
•Natrium pyruv. 6X*•NADID 6X*
•Trychinoil 6X*•Vit. C 2X*
•Ac. L(+) lacticum3X**•D e a c t i va t i o n (thr o u gh in f la m m a t i o n ) a n d n e u t r a li za t i o n o f t he im p r e gn a t e d t o xi n s*.
•S yn e r gi st i c a c t i o n wit h Fu c u s a n d t hyr o i d ho r m o n e a c t i va t i n g the sym p a t he t i c o t o n i c n e r vo u s syste m **.
•D e a c t i va t i o n (thr o u gh in f la m m a t i o n ) a n d n e u t r a li za t i o n o f t he im p r e gn a t e d t o xi n s*.
•S yn e r gi st i c a c t i o n wit h Fu c u s a n d t hyr o i d ho r m o n e a c t i va t i n g the sym p a t he t i c o t o n i c n e r vo u s syste m **.
•Pyrogenium 12X*•Fucus 3X*
•Tyrosine 2X**•Phenilalanine 2X**
•Histidine 2X**
•In a c t i ve t o xi n s m o bi li ze d t o wa r ds t he lym p ha t i c c i r c le f o r dr a i n a ge
•In a c t i ve t o xi n s m o bi li ze d t o wa r ds t he lym p ha t i c c i r c le f o r dr a i n a ge
•Lymphatic vessel 6X
•Ma t r i x hydr o lysi s*
•Ac t i o n a ga i n st t he c o n st i t u t i o n a l t e n de n c y t o im p r e gn a t i o n o f t he m a t r i x wit h t o xi n s a n d t o t he de ve lo p m e n t o f Dysmetabolic Mesenchymopathy (psychcosis).**
•Ma t r i x
•Ma t r i x hydr o lysi s*
•Ac t i o n a ga i n st t he c o n st i t u t i o n a l t e n de n c y t o im p r e gn a t i o n o f t he m a t r i x wit h t o xi n s a n d t o t he de ve lo p m e n t o f Dysmetabolic Mesenchymopathy (psychcosis).**
•Ma t r i x
•Hyaluronidase 6X*•Thuja 6/8/12/30/200X**
•Natrium sulfuricum 6/8/12/30/200X **•Prolactine 6X***
•DHEA 6X***•In c r e a se o f Fu n da m e n t a l S u bst a n c e kin e t i c s (p r o t e i n hydr o lysi s, hyp e r -i o n i c i t y, hist a m i n i c a c t i vi t y, in c r e a se d t e m p e r a t u r e ) a n d m a t r i x t u r n o ve r r a t e . *
•S ym p a t he t i c o t o n i c
•In c r e a se o f Fu n da m e n t a l S u bst a n c e kin e t i c s (p r o t e i n hydr o lysi s, hyp e r -i o n i c i t y, hist a m i n i c a c t i vi t y, in c r e a se d t e m p e r a t u r e ) a n d m a t r i x t u r n o ve r r a t e . *
•S ym p a t he t i c o t o n i c
•IL 6 4C*•DHEA 6X*
•Pyrogenium 12X*•Conjunctive Tissue 6X*
•Tyrosine 2X**•Phenilalanine 2X**
•Histidine 2X**•Prolactine 6X***
G UNA-MATRIX
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
1 3 4
•S t i m u la t i o n o f Lym p h f lo w wit h st a bi li za t i o n o f ve sse l wa ll t o n e
wit h c o n se qu e n t r e du c t i o n o f t he e xu da t e a n d t he lym p ho e de m a .
•S t i m u la t i o n o f Lym p h f lo w wit h st a bi li za t i o n o f ve sse l wa ll t o n e
wit h c o n se qu e n t r e du c t i o n o f t he e xu da t e a n d t he lym p ho e de m a .
•In hi bi t i o n o f t he p r o li f e r a t i ve
t e n de n c i e s o f t he lym p ho -
e p i t he li a l t i ssu e s
•In hi bi t i o n o f t he p r o li f e r a t i ve
t e n de n c i e s o f t he lym p ho -
e p i t he li a l t i ssu e s
•S t i m u la t i o n o f Hu m o r a l
Im m u n i t y a n d in hi bi t o r y
m o du la t i o n o f t he e xc e ssi ve
c e ll m e di a t e d c o m p e n sa t o r y
r e sp o n se
•S t i m u la t i o n o f Hu m o r a l
Im m u n i t y a n d in hi bi t o r y
m o du la t i o n o f t he e xc e ssi ve
c e ll m e di a t e d c o m p e n sa t o r y
r e sp o n se
•Re du c t i o n o f lo c a l
in f la m m a t i o n o n lym p ho -e p i t he li a l
t i ssu e s.
• Re du c t i o n o f lym p ha t i c sp a sm
du e t o in f la m m a t i o n
wit h r e st o r a t i o n o f t he lym p ha t i c
c i r c u la t i o n .
•Re du c t i o n o f lo c a l
in f la m m a t i o n o n lym p ho -e p i t he li a l
t i ssu e s.
• Re du c t i o n o f lym p ha t i c sp a sm
du e t o in f la m m a t i o n
wit h r e st o r a t i o n o f t he lym p ha t i c
c i r c u la t i o n .
G UNA-LYMPHO
REACTIVATION OF THE
LYMPHATIC
CIRCULATION
HYPERTROPHY AND HYPERPLAS IA OF THE LYMPHATIC
ORG ANS
S TRENG HTENING IMMUNE D EFENCE
ANTI-INFLAMMATORY ACTIVITY ON THE
LYMPHO-EPITHELIAL TIS S UES
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
Hydr a st i s 1XJu gla n s 3X
G r a p hi t e s 6/12/30/200X
Ma gn e si u m p ho sp ho r i c u
m 6/12/30/200X
Ju gla n s
Ma gn e si u m p ho sp ho r i c u
m 6/12/30/200X
Ju gla n s
Ca le n du la 1XPhyt o la c c a 3X
Ap i s 8XMa gn e si a p ho sp h.
6/12/30/200X
Myo so t i s 3XEqu i se t u m 3XHydr o c o t i le 1XTa r a xa c u m 1X
S a r sa p a r i lla 3XLym p ha t i c ve sse l 6XCa p i lla r y t i sssu e 6X
L-Thyr o xi n 6/12XVe i n p o r c i n e 6X
D -L Ma li c Ac . /Fu m a r i c u m Ac . /Pyr u vi c u m Ac .Tryc hi n o i l/Na t r i u m o xa la c .
1 3 5
D R A I N A G E T HE R A P Y IN P A I N M A N A G E M E N T
Directions
• G U N A - M A T R I X: 20 d r o p s t w i c e a d a y f o r a t
l e a s t 2 m o n t h s• G U N A - L YM P HO : 20 d r o p s t w i c e a d a y f o r a t
l e a s t 2 m o n t h sA L L T H E A . M . P R O D U CT S CA N BE T A KE N T O G E T H E R ( f o r e x a m p l e p u t t i n g 3 0 - 40 d r o p s o f e a c h m e d i c i n e in 1 l i t r e b o t t l e o f w a t e r . T h e p a t i e n t d r i n k s t h i s b o t t l e d u r i n g t h e w h o l e d a y)
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
1 3 7
PAIN MANAGEMENT
- LOCAL TH ERAPY -
M ore than 35% of patients suffers from M S K conditions.
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
P .R .M . in P ain
M anagement
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
Give relief to patients in a NATURAL and BIOLOGICAL WAY and WITHOUT SIDE EFFECTS.
G U N A- P O L Y A R T H R I T I SJo i n tp a i n
G U N A-M U S CL EM u s c l ep a i n
G U N A-N E CK
G U N A-S H O U L D E R
G U N A-N E U R A LN e r v ep a i n
G U N A-H I P
G U N A-T H O R A CI C
G U N A-L U M BA R
G U N A-IS CH I A L
G U N A-H A N D FO O T
Chart of area/zone connections
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
E very ampoule contains 1 0 active ingredients; 7 of them are specific for a specific type of pain or parts of the body; 3 of them are specific for pain © D i p a r t i m e n t o
S c i e n t i f i c o G u n a S . p . a .
T HE R A P E U T I C U N I T
1 421 42
I nflammationI nterleukine
I N F L A M M A T I O N
A N T I - I nflammationA ntibody
I L - 1• I L - 1 A nti-I L - 1• A nti-I L - 1
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
Interleukin 1 (I L - 1 ) cytokine secreted by macrophages, monocytes, dendritic cells, fibroblasts and endothelial cells.I L - 1 S U P P O R T S I N F L A M M A T O R Y
P R O CE S S E S© D i p a r t i m e n t o
S c i e n t i f i c o G u n a S . p . a .
INTERLEUKINE-1 (α; ß)
IL-1 (α; ß) ACTION MECHANISM
I L - 1 (α; ß) a c t i v a t e s :1 . cyclooxygenase type 2(CO X2)2.prostaglandin E 2 (P G E 2)3.prostaglandin D 2 (P G D 2)4.nitric oxide (N O )
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
I L - 1
IN F L A M M A T I O NS YN O VI A L P A N N U S
F O R M A T I O N
CA R T I L A G E BR E A KD O WN S
BO N E R E S O R P T I O N
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
CONVENTIONAL DRUGS TO STOP INTERLEUKINE-1 EFFECTS
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
N S A ID s
CO R TI S O N
A S A
- - -CO X2 P G E 2/
D 2N O
Low dose SKA-activated Antibody AntiInterleukins -1 (α and β) in Pain
Management
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
A nti I L - 1
I L-1
CO X2
P GE 2
N O
-BL O CK
A ntiI n t e r l e u k i n - 1 (α; ß) acts a s N S A I D s , cortisone and, in part, as salicylate , w i t h o u t t h e n e g a t i v e s i d e e f f e c t s c a u s e d b y
β-END ORPHIN
En do r p hi n s a r e o r g a n i c c he mi c a l s ubs t a n c e s p r o duc e d by t he CNS, ha vi n g a n t i p a i n a n d p hys i o l o g i c a l c ha r a c t e r i s t i c s s imi l a r t o t ho s e o f morphine a n d opium – ho we ve r t he y ha ve a wide r r a n g e .
En do r p hi n s , l i ke a n umbe r o f a l ka l o i ds , s uc h a s mo r p hi n , c a n c a us e s t a t e s o f e up ho r i a a n d s l e e p n e s s a c c o r di n g t o t he qua n t i t y r e l e a s e d.
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
H E A L T H
P HYS I O L O G I CA L CO N CE N T R A T I O N
1 0- 6
1 0-1 5
4C – X6
Concentration of A nti I L - 1 (α; β) and β- endorphin
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
• A R N I CA (Arnica montana)• A CO N I T U M (Aconitum napellus)• R HU S T O X. (Rhus toxicodendron)• CIM I CI F U G A (Cimicifuga racemosa)• VIO L A O D O R A T A • CA U L O P HYL L U M (Caulophyllum talictroides)• A CI D U M BE N ZO I CU M• L E D U M (Ledum palustre)• CO L O CYN T HI S (Citrullus colocynthis)
Important homeopatic single remedies in P .R .M . P ain
M anagement ampoules:• A CI D U M F O R M I CI CU M• G N A P HA L I U M P O L YCE P HA L U M• R HO D O D E N D R O N CHR YS A N T HU M• L A CHE S I S M U T U S• BR YO N I A A L BA• HYP E R I CU M P E R F O R A T U M• BE L L A D O N N A (Atropa belladonna)• CR O T A L U S HO R R I D U S• KA L M I A L A T I F O L I A• E T C.
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
1 52
• S t a n d a r d p r o t o c o l f o r i . m . a d m i n i s t r a t i o n : 1 a m p o u l e 1 - 3 t i m e s a w e e k a c c o r d i n g t o s e v e r i t y a n d c l i n i c a l e v o l u t i o n .
• S t a n d a r d p r o t o c o l a c c o r d i n g t o m e s o t h e r a p e u t i c t e c h n i qu e : 1 - 2 a m p o u l e s p e r t r e a t m e n t : 2 t r e a t m e n t s f o r t h e f i r s t 2 w e e k s , t h e n 1 t r e a t m e n t a w e e k t i l l p a i n r e l i e f ( a v e r a g e 8- 1 0 s e s s i o n s ). Fo r c h r o n i c p a t h o l o g i e s : c o n t i n u e 1 t r e a t m e n t a
P A I N M A N A G E M E N T
T R E A T M E N T P R O T O CO L
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
S U P P O R T I VE O R A L T HE R A P Y IN
P A I N M A N A G E M E N T
Directions• G U N A - F L A M : 20 d r o p s t w i c e a d a y f o r a t
l e a s t 2 m o n t h s
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
• Mo du la t i o n o f t he n e u r o ge n i c p ha se o f in f la m m a t i o n *.
• S e n si t i za t i o n o f the be t a -e n do r p hi n p e r i p he r a l r e c e p t o r s**.
• RES (r e t i c u lo e n do t he lia l syste m ) st i m u la t i o n a n d in hi bi t i o n o f the p o ssi ble se p t i c p r o gr e ssi o n o f the in f la m m a t o r y p r o c e ss.
Ho m e o p a t hi c a n d Mo le c u la r Bio lo gy
r e m e di e s… in 1 sin gle dr u g: G UNA-FLAM
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
Ac o n i t u m *Be lla do n n a *
Fe r r u m p ho sp ho r i c u m *Ap i s*
Br yo n i a *Pyr o ge n i u m *
Phyt o la c c a *Na t r i u m p yr u vi c u m *
Ac i du m c i t r i c u m *Cu -glu c o n a t e *An t i IL 1-a lf a **TG F 1 be t a ***
IL 10***
• Mo du la t i o n o f the n e u r o ge n i c , va sc u la r e xu da t i ve p ha se s o f t he in f la m m a t o r y p r o c e ss*.
• In hi bi t i o n o f t he in f la m m a t o r y c a sc a de st a r t i n g p o i n t **.
• Po t e n t i a t i o n o f im m u n o lo gi c a n t i -in f la m m a t o r y a c t i vi t y ha vi n g Th2-Th3 p o la r i t y***.
Ac o n i t u m *Be t a -e n do r p hi n **
He p a r su lf u r i sPyr o ge n i u m
Fe r r u m p ho sp ho r i c u m
Me la t o n i n 4CHyp o p hysi s p o r c i n e 200X
Pin e a l G la n d 6XCo n ju n c t i va t i ssu e 12X
• Re gu la t i o n o f ECM (e xt r a c e llu la r m a t r i x) f u n c t i o n t hr o u gh m o du la t i o n o f hyp o p hyse a l ho r m o n e a c t i o n a n d p i n e a l gla n d st i m u la t i o n
D R A I N A G E T HE R A P Y IN P A I N M A N A G E M E N T
Directions• G U N A - M A T R I X: 20 d r o p s t w i c e a d a y f o r a t
l e a s t 2 m o n t h s
+• G U N A - L YM P HO : 20 d r o p s t w i c e a d a y f o r a t
l e a s t 2 m o n t h s
A L L T H E A . M . P R O D U CT S CA N BE T A KE N T O G E T H E R ( f o r e x a m p l e p u t t i n g 3 0 - 40 d r o p s o f e a c h m e d i c i n e in 1 l i t r e ( 3 3 f l o z) b o t t l e o f w a t e r . T h e p a t i e n t d r i n k s t h i s “t h e r a p e u t i c c o c k t a i l ” d u r i n g t h e w h o l e d a y). © D i p a r t i m e n t o
S c i e n t i f i c o G u n a S . p . a .
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
1 56
• WHE R E : intradermal• HO W M A N Y P O I N T S : 5- 6- 7• HO W M U CH: 0.3- 0.5 ml each injection
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
S YR I N G E S F O R P A I N
M A N A G E M E N T
2,5 ml
5 ml 1 0 ml
20 ml
IN S UL I N
1 3 m m.
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
N E E D L E S F O R P A I N M A N A G E M E N T
30 G
L E N G HT
G A U G E
1 59
• Pa i n s ymp t o ma t o l o g y r e duc t i o n by me a n s o f UP-REGULATION o f b–En do r p hi n r e c e p t o r s
• Pa i n s ymp t o ma t o l o g y r e duc t i o n by me a n s o f UP-REGULATION o f b–En do r p hi n r e c e p t o r s
• Mo dul a t i o n o f IL1 a a n d IL1 b p r o -in fl a mma t o r y a c t i vi t y in the t r i g g e r p ha s e o f in fl a mma t i o n
• Mo dul a t i o n o f IL1 a a n d IL1 b p r o -in fl a mma t o r y a c t i vi t y in the t r i g g e r p ha s e o f in fl a mma t i o n
• Re duc t i o n o f de g e n e r a t i ve a r t i c ul a r p a i n o n a c hr o n i c -e vo l ut i ve ba s i s
• Re duc t i o n o f de g e n e r a t i ve a r t i c ul a r p a i n o n a c hr o n i c -e vo l ut i ve ba s i s
• Re duc t i o n o f p o l ya r t i c ul a r p a i n s ymp t o ma t o l o g y in a c ut e in fl a mma t i o n ha vi n g diffe r e n t lo c a l i za t i o n
• Re duc t i o n o f p o l ya r t i c ul a r p a i n s ymp t o ma t o l o g y in a c ut e in fl a mma t i o n ha vi n g diffe r e n t lo c a l i za t i o n
•Be t a -En do r p hi n 4C
•An t i in t e r le u ki n 1 a lp ha 4C
•An t i in t e r le u ki n 1 be t a 4C
•Le dum p a l us t r e 8X•Vis c um a lbum 10X
P.N. E. I. a n t a lgi c
c o r eAn t i -
i n f la m ma t o r y c o r e
Chr o n i c in f la m m a t o
r y p a i n
Ac u t e in f la m m
a t o r y p a i n
•Sa l yc i l i c um a c idum 2X
•Ac o n i t um 6X
•Dro s e r a 8X
•Co l c hi c um a ut umn a l e 10X
•Gua i a c um 10X
Exa m p le o f P. R. M. Pa i n Ma n a ge m e n t a m p o u le :
GUNA®-POLYARTH RITIS
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
1 6 0
Cl i n i c a l In di c a t i o n s
GUNA®-NECK
Ne c k p a i n due t o c a r t i l a g e de g e n e r a t i ve c e r vi c a l s p i n e dis o r de r s (c e r vi c a l o s t e o a r t hr o s i s ) Ne c k p a i n due t o c e r vi c a l mus c ul a r t r i g g e r p o i n t s St i ff n e c k s yn dr o me Simp l e n e c k p a i n Whip l a s h Po s t ur a l n e c k a c he Me c ha n i c a l imba l a n c e (fa c e t jo i n t s yn dr o me ) Ce r vi c a l s p i n a l l i g a me n t s yn dr o me Ce r vi c a l s p i n a l n e r ve r o o t p a i n© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
1 6 1
• Riduzi o n e de l l a s i n t o ma t o l o g i a a l g i c a p e r UP-REGULATION de i r e c e t t o r i de l l a b–En do r fi n a
• Riduzi o n e de l l a s i n t o ma t o l o g i a a l g i c a p e r UP-REGULATION de i r e c e t t o r i de l l a b–En do r fi n a
• Mo dul a t i o n o f IL1 a a n dIL1 b p r o -i n fl a mma t o r y a c t i vi t y in the t r i g g e r p ha s e o f in fl a mma t i o n
• Mo dul a t i o n o f IL1 a a n dIL1 b p r o -i n fl a mma t o r y a c t i vi t y in the t r i g g e r p ha s e o f in fl a mma t i o n
Re duc t i o n o f c e r vi c a l r a c hi s p a i n
s ymp t o ma t o l o g y o f diffe r e n t o r i g i n :
• Fibr o mya l g i c o r i g i n (Picricum acidum)
• Sp a s t i c a n d/o r c o n g e s t i ve o r i g i n (Crotalus horr., Nux vomica, Magnesia phosph.)
• Ne vr a l g i c o r i g i n (Magnesia phosph.)An a e s t he t i c o r i g i n :
• Picricum acidum
Re duc t i o n o f c e r vi c a l r a c hi s p a i n
s ymp t o ma t o l o g y o f diffe r e n t o r i g i n :
• Fibr o mya l g i c o r i g i n (Picricum acidum)
• Sp a s t i c a n d/o r c o n g e s t i ve o r i g i n (Crotalus horr., Nux vomica, Magnesia phosph.)
• Ne vr a l g i c o r i g i n (Magnesia phosph.)An a e s t he t i c o r i g i n :
• Picricum acidum
• Bio s t imul a t i o n c a r t i l a g e ma t r i x c o mp o n e n t s s yn t he s i s (Cartilago)
• An t i -de g e n e r a t i ve a c t i o n (Discus intervertebralis)
• Bio s t imul a t i o n c a r t i l a g e ma t r i x c o mp o n e n t s s yn t he s i s (Cartilago)
• An t i -de g e n e r a t i ve a c t i o n (Discus intervertebralis)
• Be t a -En do r p hi n 4C
• An t i in t e r l e uki n 1 a l p ha 4C
• An t i in t e r l e uki n 1 be t a 4C
• Ma g n e s i a p ho s p ho r i c a 12X
•Pic r i c um a c . 8X
• Cro t a l us ho r r i dus 10X
• Nux vo mi c a 10X
• Sil i c e a 4X
• St imul a t i o n o f o s t e o bl a s t s fun c t i o n a n d c o r r e c t i o n o f a r t i c ul a r s t r uc t ur e p a t ho l o g i e s
• St imul a t i o n o f o s t e o bl a s t s fun c t i o n a n d c o r r e c t i o n o f a r t i c ul a r s t r uc t ur e p a t ho l o g i e s
• Ca r t i l a g o s ui s 4X
•In t e r ve r t e br a l dis k, Po r c i n e 4X
An t i -de g e n e r a t ive c o r e 2
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
GUNA®-NECK
• Pa i n s ymp t o ma t o l o g y r e duc t i o n by me a n s o f UP-REGULATION o f b–En do r p hi n r e c e p t o r s
• Pa i n s ymp t o ma t o l o g y r e duc t i o n by me a n s o f UP-REGULATION o f b–En do r p hi n r e c e p t o r s P.N.E.I.
a n t a l g i c c o r e
H o me o p a t hic a n t a l g i c
c o r e
An t i -in fl a mma t o
ry c o r e
An t i -de g e n e r at i ve c o r e
1
1 6 2
in t o s p e c i fi c a n d s e l e c t e d
lo c a l Ac up un c t ur e Po i n t s
GUNA®-NECK
GV 16
GB 20
BL 10
GV 15
GB 21
GV 14
SI 9
SI 10
GB 21
1 6 3
in t o Tr i g g e r Po i n t s a n d r e fe r r e d p a i n zo n e s
GUNA®-NECK
BL 10
BL 11
TP = Ma i n Tr i g g e r Po i n t s a n d c o r r e l a t e d Ac up un c t ur e p o i n t s
TP
TP
SI 15
TP/SI 14
C 7 C 7
1 6 4
GUNA®-TH ORACICCl i n i c a l
In di c a t i o n sTho r a c i c p a i n due t o c a r t i l a g e de g e n e r a t i ve t ho r a c i c s p i n e dis o r de r s (t ho r a c i c o s t e o a r t hr o s i s ) Tho r a c i c p a i n due t o s c o l i o s i s Tho r a c i c p a i n due t o t ho r a c i c lo n g mus c l e t r i g g e r p o i n t s Pa i n due t o t ho r a c i c s p i n e o s t e o p hyt o s i s Simp l e p o s t e r i o r t ho r a c i c p a i n (t ho r a c i c p a i n s yn dr o me ) Me c ha n i c a l imba l a n c e (c o s t o -ve r t e br a l fa c e t jo i n t s yn dr o me ) Tho r a c i c s p i n a l l i g a me n t s yn dr o me Tho r a c i c s p i n a l n e r ve r o o t p a i n Pa i n fr o m s p i n a l o s t e o p o r o s i s
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
1 6 5
• Riduzi o n e de l l a s i n t o ma t o l o g i a a l g i c a p e r UP-REGULATION de i r e c e t t o r i de l l a b–En do r fi n a
• Riduzi o n e de l l a s i n t o ma t o l o g i a a l g i c a p e r UP-REGULATION de i r e c e t t o r i de l l a b–En do r fi n a
Re duc t i o n o f the do r s a l ra c hi s p a i n s ymp t o ma t o l o g y o f
diffe r e n t o r i g i n , typ e a n d lo c a l i za t i o n :
Ne ur o -mus c ul a r o r i g i n (Cimicifuga, Chininum
sulph., Conium)
•Sp a s t i c a n d/o r c o n g e s t i ve o r i g i n (Chelidonium, Spongia)
LOCALIZATION
Do r s a l ra c hi s : dir e c t , a l l ; he p a t i c r e fl e x, Chelidonium.
In t e r c o s t a l p a i n : Spongia
Re duc t i o n o f the do r s a l ra c hi s p a i n s ymp t o ma t o l o g y o f
diffe r e n t o r i g i n , typ e a n d lo c a l i za t i o n :
Ne ur o -mus c ul a r o r i g i n (Cimicifuga, Chininum
sulph., Conium)
•Sp a s t i c a n d/o r c o n g e s t i ve o r i g i n (Chelidonium, Spongia)
LOCALIZATION
Do r s a l ra c hi s : dir e c t , a l l ; he p a t i c r e fl e x, Chelidonium.
In t e r c o s t a l p a i n : Spongia
•An t i -de g e n e r a t i ve a n d a n t i -n e ur a l g i c a c t i o n•An t i -de g e n e r a t i ve a n d a n t i -n e ur a l g i c a c t i o n
• Be t a -En do r p hi n 4C
• An t i in t e r l e uki n 1 a l p ha 4C
• An t i in t e r l e uki n 1 be t a 4C
•Che l i do n ium ma jus 4X
•Cimi c i fug a ra c e mo s a 4X
•Co n ium ma c ul a t um 6X
•Chin i n um s ul p hur i c um 8X
•Sp o n g i a to s t a 10X
• Ca l c a r e a p ho s p ho r i c a 6X
•Co n s t i t ut i o n a l c o r r e c t i o n o f a r t i c ul a r s t r uc t ur e p a t ho l o g i e s
•Co n s t i t ut i o n a l c o r r e c t i o n o f a r t i c ul a r s t r uc t ur e p a t ho l o g i e s
•In t e r ve r t e br a l dis k, Po r c i n e 4X
Co n s t i t ut i o na l c o r e
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
GUNA®-TH ORACIC
• Pa i n s ymp t o ma t o l o g y r e duc t i o n by me a n s o f UP-REGULATION o f b–En do r p hi n r e c e p t o r s
• Pa i n s ymp t o ma t o l o g y r e duc t i o n by me a n s o f UP-REGULATION o f b–En do r p hi n r e c e p t o r s
• Mo dul a t i o n o f IL1 a a n d IL1 b p r o -in fl a mma t o r y a c t i vi t y in the t r i g g e r p ha s e o f in fl a mma t i o n
• Mo dul a t i o n o f IL1 a a n d IL1 b p r o -in fl a mma t o r y a c t i vi t y in the t r i g g e r p ha s e o f in fl a mma t i o n
P.N.E.I. a n t a l g i c
c o r e
H o me o p a t hic a n t a l g i c
c o r e
An t i -in fl a mma t o
ry c o r e
An t i -de g e n e r at i ve c o r e
1 6 6
GUNA®-LUMBARCl i n i c a l
In di c a t i o n s Lumba r p a i n due t o c a r t i l a g e de g e n e r a t i ve lumba r s p i n e dis o r de r s (lumba r a n d lumba r -s a c r a l a r t hr o s i s ) Lumba r ve r t e br a l o s t e o p hyt o s i s Lo w ba c k p a i n due t o mus c ul a r a n d t e n di n o us t r i g g e r p o i n t s Simp l e lumba r p a i n (lo w ba c k s yn dr o me ) We a k lo w ba c k s yn dr o me Po s t ur a l lo w ba c k a c he Lumba r a n d lumba r -s a c r a l me c ha n i c a l imba l a n c e Lumba r a n d lumba r -s a c r a l s p i n a l l i g a me n t s yn dr o me Sa c r o -i l i a c s yn dr o me Sp i n a l lumba r a n d lumba r -s a c r a l n e r ve r o o t p a i n
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
1 6 7
•Pa i n s ymp t o ma t o l o g y r e duc t i o n by me a n s o f UP-REGULATION o fb–En do r p hi n r e c e p t o r s
•Pa i n s ymp t o ma t o l o g y r e duc t i o n by me a n s o f UP-REGULATION o fb–En do r p hi n r e c e p t o r s
•Mo dul a t i o n o f IL1 a a n d IL1 b p r o -in fl a mma t o r y a c t i vi t y in the t r i g g e r p ha s e o f in fl a mma t i o n
•Mo dul a t i o n o f IL1 a a n d IL1 b p r o -in fl a mma t o r y a c t i vi t y in the t r i g g e r p ha s e o f in fl a mma t i o n•An t i -de g e n e r a t i ve
a n d a n t i -n e ur a l g i c a c t i o n
•An t i -de g e n e r a t i ve a n d a n t i -n e ur a l g i c a c t i o n
Re duc t i o n o f the lumba r r a c hi s p a i n
s ymp t o ma t o l o g y o f diffe r e n t o r i g i n , typ e
a n d lo c a l i za t i o n :
•Ne ur o -mus c ul a r o r i g i n (Bryonia, Alumina, Ac. Phosphoricum). Ar t i c ul a r o r i g i n (Natrium sulph.)
•Typ e – c r a mp -l i ke p a i n (Ac. phosphoricum); mus c ul a r p a r e s i s p he n o me n a (Alumina)
•Lo c a l i za t i o n –Lumbo s a c r a l r a c hi s : dir e c t , Hamamelis; a bdo mi n a l r e fl e x, Sepia
Re duc t i o n o f the lumba r r a c hi s p a i n
s ymp t o ma t o l o g y o f diffe r e n t o r i g i n , typ e
a n d lo c a l i za t i o n :
•Ne ur o -mus c ul a r o r i g i n (Bryonia, Alumina, Ac. Phosphoricum). Ar t i c ul a r o r i g i n (Natrium sulph.)
•Typ e – c r a mp -l i ke p a i n (Ac. phosphoricum); mus c ul a r p a r e s i s p he n o me n a (Alumina)
•Lo c a l i za t i o n –Lumbo s a c r a l r a c hi s : dir e c t , Hamamelis; a bdo mi n a l r e fl e x, Sepia
•Be t a -En do r p hi n 4C
•An t i in t e r l e uki n 1 a l p ha 4C
•An t i in t e r l e uki n 1 be t a 4C
In t e r ve r t e br a l dis k, Po r c i n e 4X
P.N.E.I.
An t a l g i c c o r e
An t i -in fl a mma t o
r y c o r e
An t i -de g e n e r a t i v
e c o r e
H o me o p a t hic a n t a l g i c
c o r e
•Br yo n i a 4X•Se p i a o ffi c i n a l i s 4X
•Pho s p ho r i c um a c . 6X •H a ma me l i s vir g i n i a n a 6X
•Alumi n a 8X•Na t r um s ul p hur i c um 8X
GUNA®-LUMBAR
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
1 6 8
GUNA®-ISCH IALCl i n i c a l
In di c a t i o n s
Sc i a t i c a p a i nLumba r -s c i a t i c p a i nNe r ve p a i n in t he lo we r lumba r s p i n e Le g n e r ve p a i n due t o p o s t -s ur g e r y t r e a t me n t o f dis k he r n i a t i o n L4-L5, L5-S1Mo r t o n n e ur o ma © Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
1 6 9
P.N.E.I. a n t a l g i c
c o r e
An t i -in fl a mma t o r
y c o r e
Pr ima r y n e ur a l g i c
p a i n
Se c o n da r y n e ur a l g i c
p a i n
• Pa i n s ymp t o ma t o l o g y r e duc t i o n by me a n s o f UP-REGULATION o f b–En do r p hi n r e c e p t o r s
• Pa i n s ymp t o ma t o l o g y r e duc t i o n by me a n s o f UP-REGULATION o f b–En do r p hi n r e c e p t o r s
• Mo dul a t i o n o f IL1 aa n d IL1 b p r o -in fl a mma t o r y a c t i vi t y in the t r i g g e r p ha s e o f in fl a mma t i o n
• Mo dul a t i o n o f IL1 aa n d IL1 b p r o -in fl a mma t o r y a c t i vi t y in the t r i g g e r p ha s e o f in fl a mma t i o n
Mo dul a t i o n o f s c i a t i c p a i n by me a n s o f in fl a mma t i o n n e ur o g e n p ha s e in hi bi t i o n (Aconitum and Arsenicum) a n d dir e c t a c t i o n o n the s c i a t i c n e r ve (Gnaphalium)
Mo dul a t i o n o f s c i a t i c p a i n by me a n s o f in fl a mma t i o n n e ur o g e n p ha s e in hi bi t i o n (Aconitum and Arsenicum) a n d dir e c t a c t i o n o n the s c i a t i c n e r ve (Gnaphalium)
• Pa i n mo dul a t i o n by me a n s o f a r e duc t i o n in the p r o g r e s s i o n o f o s t e o c ho n dr o s i s (Cimicifuga), c o xo -fe mo r a l a r t hr o s i s (Rhus tox.),ba c ka c he (Rhus tox).
• Pa i n mo dul a t i o n by me a n s o f a r e duc t i o n in the p r o g r e s s i o n o f o s t e o c ho n dr o s i s (Cimicifuga), c o xo -fe mo r a l a r t hr o s i s (Rhus tox.),ba c ka c he (Rhus tox).
• Be t a -En do r p hi n 4C
• An t i in t e r l e uki n 1 a l p ha 4C
• An t i in t e r l e un i n 1 be t a 4C
•La c he s i s mutus 8X
•Gn a p ha l i um p o l yc e p ha lum 4X
•Ar s e n i c um a l bum 6X
•Rho do de n dr o n c hr ys a n t um 6X
•Ac o n i t um n a p e l l us 8X
• Cimi c i fug a 4X
• La c he s i s mutus 8X
• Mo dul a t i o n o f a bdo mi n a l wa l l r e fl e xe d s c i a t i c p a i n (Lachesis) a n d il i a c -s a c r a l lumba r p a i n (Cimicifuga)
• Mo dul a t i o n o f a bdo mi n a l wa l l r e fl e xe d s c i a t i c p a i n (Lachesis) a n d il i a c -s a c r a l lumba r p a i n (Cimicifuga)
•Cimi c i fug a 4X
•Rhus to xi c o de n dr o n 4X
Re fl e xe d n e ur a l g i c
p a i n
GUNA®-ISCH IAL
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
1 70
GUNA®-SH OULDERCl i n i c a l
In di c a t i o n s
Sc a p ul a r -hume r a l p e r i -a r t hr i t i s
Sho ulde r p a i n
Sho ul de r -a r m s yn dr o me
Fr o ze n s ho ul de r
Sho ul de r p a i n due t o dis l o c a t i o n ,
t he r a p e ut i c r e s t
Ep i c o n dyl i t i s
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
1 71
• Pa i n s ymp t o ma t o l o g y r e duc t i o n by me a n s o f UP-REGULATION o f b–En do r p hi n r e c e p t o r s
• Pa i n s ymp t o ma t o l o g y r e duc t i o n by me a n s o f UP-REGULATION o f b–En do r p hi n r e c e p t o r s
• Mo dul a t i o n o f IL1 a a n d IL1 b p r o -in fl a mma t o r y a c t i vi t y in the t r i g g e r p ha s e o f in fl a mma t i o n
• Mo dul a t i o n o f IL1 a a n d IL1 b p r o -in fl a mma t o r y a c t i vi t y in the t r i g g e r p ha s e o f in fl a mma t i o n• An t i -de g e n e r a t i ve a n d
c hr o n i c a n t i -i n fl a mma t o r y a c t i o n (Tendon, Porcine)
• An t i -de g e n e r a t i ve a n d c hr o n i c a n t i -i n fl a mma t o r y a c t i o n (Tendon, Porcine)
Re duc t i o n o f s ho ulde r p a i n o f diffe r e n t o r i g i n a n d typ e :
• Ne ur a l g i c o r i g i n (Argentum nitricum, Ferrum phosph., Iris)
• Mus c ul a r o r i g i n (Ranunculus, Sanguinaria)
• Ac ut e p a i n (Ferrum, Iris)
• Chr o n i c p a i n (Argentum nitricum, Ranunculus)
Re duc t i o n o f s ho ulde r p a i n o f diffe r e n t o r i g i n a n d typ e :
• Ne ur a l g i c o r i g i n (Argentum nitricum, Ferrum phosph., Iris)
• Mus c ul a r o r i g i n (Ranunculus, Sanguinaria)
• Ac ut e p a i n (Ferrum, Iris)
• Chr o n i c p a i n (Argentum nitricum, Ranunculus)
•Be t a -En do r p hi n 4C
•An t i in t e r l e uki n 1 a l p ha 4C
•An t i in t e r l e uki n 1 be t a 4C
•Ca r t i l a g o s ui s 4X•Te n do n , Po r c i n e 6X
P.N.E.I. a n t a l g i c
c o r e
An t i -in fl a mma t o
r y c o r e
An t i -de g e n e r at i ve c o r e
H o me o p athi c
a n t a l g i c c o r e
•Arg e n t um n i t r i c um 8X
•Fe r r um p ho s p ho r i c um 8X
•Ir i s ve r s i c o l o r 8X
•Sa n g ui n a r i a c a n a de n s i s 8X
• Ra n un c ulus bulbo s us 10X
GUNA®-SH OULDER
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
1 72
GUNA®-H ANDFOOTCl i n i c a l
In di c a t i o n sOs t e o a r t hr i t i s o f dig i t s p a i nRhizo a r t hr o s i s o f t he t humb (Fo r e s t i e r dis e a s e )Ar t hr o s i s p a i n due t o ha mme r t o eCa r p a l -t un n e l s yn dr o me De Que r va i n dis e a s eMe t a c a r p a l a n d Me t a t a r s a l p a i nMo r t o n dis e a s e Rhe uma t o i d a r t hr i t i s o f ha n d/fo o tH a n d/Fo o t t e n do n p a i n due t o p r o l o n g e d
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
1 73
P.N.E.I.
a n t a l g i c c o r e
An t i -in fl a mma t o r
y c o r e
In fl a mma t ory p a i n
De g e n e r at i ve p a i n
• Pa i n s ymp t o ma t o l o g y r e duc t i o n by me a n s o f UP-REGULATION o f b–En do r p hi n r e c e p t o r s
• Pa i n s ymp t o ma t o l o g y r e duc t i o n by me a n s o f UP-REGULATION o f b–En do r p hi n r e c e p t o r s
• Mo dul a t i o n o f IL1 aa n d IL1 b p r o -in fl a mma t o r y a c t i vi t y in the t r i g g e r p ha s e o f in fl a mma t i o n
• Mo dul a t i o n o f IL1 aa n d IL1 b p r o -in fl a mma t o r y a c t i vi t y in the t r i g g e r p ha s e o f in fl a mma t i o n
Pa i n mo dul a t i o n by me a n s o f a c ut e in fl a mma t i o n p he n o me n a – va s a l in p a r t i c ul a r –in hi bi t i o n (a r t hr o s i s t yp e )
Pa i n mo dul a t i o n by me a n s o f a c ut e in fl a mma t i o n p he n o me n a – va s a l in p a r t i c ul a r –in hi bi t i o n (a r t hr o s i s t yp e )
• Pa i n mo dul a t i o n by me a n s o f de g e n e r a t i ve p r o c e s s (a r t hr o s i s t yp e ) in hibi t i o n
• Pa i n mo dul a t i o n by me a n s o f de g e n e r a t i ve p r o c e s s (a r t hr o s i s t yp e ) in hibi t i o n
• Be t a -En do r p hi n 4C
• An t i in t e r l e uki n 1 a l p ha 4C
• An t i in t e r l e uki n 1 be t a 4C
•Arn i c a mo n t a n a 4X
•Ca ul o p hi l l um tha l i c t r o ide s 12X
•Le dum p a l us t r e 6X
•Be n zo i c um a c idum 6X
• Pa i n mo dul a t i o n by me a n s o f ur i c a c id c r ys t a l s a c c umul a t i o n in hi bi t i o n (dra i n a g e a c t i o n )
• Pa i n mo dul a t i o n by me a n s o f ur i c a c id c r ys t a l s a c c umul a t i o n in hi bi t i o n (dra i n a g e a c t i o n )
•Vio l a o do r a t a 6X
•Me r c ur ius s o lubi l i s 8X
•Cimi c i fug a ra c e mo s a 10X
Go ut p a i n
GUNA®-H ANDFOOT
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
1 74
GUNA®-H IPCl i n i c a l
In di c a t i o n s
H i p jo i n t
o s t e o a r t hr o s i sH i p jo i n t c a p s ul e in fl a mma t i o nH i p jo i n t r he uma t o id a r t hr i t i s H i p jo i n t p a i n o f mus c l e o r i g i n H i p jo i n t p a i n o f n e r ve o r i g i n (bur n i n g hip )H i p jo i n t p a i n due t o
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
1 75
P.N.E.I. a n t a l g i c
c o r e
H o me o p a t hic a n t a l g i c
c o r e
An t i -in fl a mma t o
ry c o r eCo n s t i t ut i on a l c o r e
An t i -de g e n e r a t i v
e c o r e
• Pa i n s ymp t o ma t o l o g y r e duc t i o n by me a n s o f UP-REGULATION o f b–En do r p hi n r e c e p t o r s
• Pa i n s ymp t o ma t o l o g y r e duc t i o n by me a n s o f UP-REGULATION o f b–En do r p hi n r e c e p t o r s
• Mo dul a t i o n o f IL1 aa n d IL1 b p r o -in fl a mma t o r y a c t i vi t y in the t r i g g e r p ha s e o f in fl a mma t i o n
• Mo dul a t i o n o f IL1 aa n d IL1 b p r o -in fl a mma t o r y a c t i vi t y in the t r i g g e r p ha s e o f in fl a mma t i o n
Re duc t i o n o f hip p a i n s ymp t o ms o f r he uma t i c o r i g i n
:
• Ca p s ul e (Formicum ac., Argentum)
• Te n do n s a n d li g a me n t s (Rhus tox)
• Ne r ve s (Colocynthis)
• Mus c l e s (Arnica)
Re duc t i o n o f hip p a i n s ymp t o ms o f r he uma t i c o r i g i n
:
• Ca p s ul e (Formicum ac., Argentum)
• Te n do n s a n d li g a me n t s (Rhus tox)
• Ne r ve s (Colocynthis)
• Mus c l e s (Arnica)
• Bio s t imul a t i o n o f c a r t i l a g i n e o us ma t r i x c o mp o n e n t s s yn t he s i s (Cartilago)
• Ne w ve s s e l s de ve l o p me n t s t imul a t i o n (Argentum)
• Bio s t imul a t i o n o f c a r t i l a g i n e o us ma t r i x c o mp o n e n t s s yn t he s i s (Cartilago)
• Ne w ve s s e l s de ve l o p me n t s t imul a t i o n (Argentum)
• Be t a -En do r p hi n 4C
• An t i in t e r l e uki n 1 a l p ha 4C
• An t i in t e r l e uki n 1 be t a 4C
•Arg e n t um me t a l l i c um 6X
•Arn i c a mo n t a n a 8X
•Co l o c yn t hi s 8X
•Fo r mi c um a c . 8X
• Rhus to xi c o de n dr o n 10X
• Ca l c a r e a fluo r i c a 6X
• Co n s t i t ut i o n a l c o r r e c t i o n o f a r t i c ul a r s t r uc t ur e p a t ho l o g y
• Co n s t i t ut i o n a l c o r r e c t i o n o f a r t i c ul a r s t r uc t ur e p a t ho l o g y
• Ca r t i l a g o s ui s 4X
• Arg e n t um me t a l l i c um 6X
GUNA®-H IP
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
1 76
GUNA®-POLYARTH RITISCl i n i c a l
In di c a t i o n s Sma l l jo i n t s r he uma t o i d a r t hr i t i s o f ha n d a n d fo o t Co s t o -s t e r n a l s yn dr o me (Tie t ze s yn dr o me ) Chr o n i c p o l ya r t hr i t i s due t o a ut o -immun e dis e a s e s (e .g . Lup us e r yt he ma t o s us s i s t e mi c us ) Br o ke n bo n e s yn dr o me due t o vir a l o r p r o t o zo i c dis e a s e Jo i n t p a i n due t o c a n c e r dis e a s e (c hr o n i c le uke mi a , mo n o c l o n a l blo o d dis e a s e s )
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
1 77
• Pa i n s ymp t o ma t o l o g y r e duc t i o n by me a n s o f UP-REGULATION o f b–En do r p hi n r e c e p t o r s
• Pa i n s ymp t o ma t o l o g y r e duc t i o n by me a n s o f UP-REGULATION o f b–En do r p hi n r e c e p t o r s
• Mo dul a t i o n o f IL1 a a n d IL1 b p r o -in fl a mma t o r y a c t i vi t y in the t r i g g e r p ha s e o f in fl a mma t i o n
• Mo dul a t i o n o f IL1 a a n d IL1 b p r o -in fl a mma t o r y a c t i vi t y in the t r i g g e r p ha s e o f in fl a mma t i o n
• Re duc t i o n o f de g e n e r a t i ve a r t i c ul a r p a i n o n a c hr o n i c -e vo l ut i ve ba s i s
• Re duc t i o n o f de g e n e r a t i ve a r t i c ul a r p a i n o n a c hr o n i c -e vo l ut i ve ba s i s
• Re duc t i o n o f p o l ya r t i c ul a r p a i n s ymp t o ma t o l o g y in a c ut e in fl a mma t i o n ha vi n g diffe r e n t lo c a l i za t i o n
• Re duc t i o n o f p o l ya r t i c ul a r p a i n s ymp t o ma t o l o g y in a c ut e in fl a mma t i o n ha vi n g diffe r e n t lo c a l i za t i o n
•Be t a -En do r p hi n 4C
•An t i in t e r l e uki n 1 a l p ha 4C
•An t i in t e r l e uki n 1 be t a 4C
•Le dum p a l us t r e 8X•Vis c um a lbum 10X
P.N.E.I. a n t a l g i c
c o r e
An t i -in fl a mma t o
r y c o r e
Chr o n i c in fl a mma t o r y
p a i n
Ac ut e in fl a mma t o r
y p a i n
•Sa l yc i l i c um a c idum 2X
•Ac o n i t um 6X
•Dro s e r a 8X
•Co l c hi c um a ut umn a l e 10X
•Gua i a c um 10X
GUNA®-POLYARTH RITIS
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
1 78
GUNA®-MUSCLECl i n i c a l
In di c a t i o n sTr i g g e r p o i n t s ma n a g e me n t : a c ut e , s uba c ut e , c hr o n i c
Fibr o mya l g i a s yn dr o me
Re fe r r e d s o ma t i c p a i n a r e a ma n a g e me n t
De r ma t o myo s i t i s© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
1 79
Ac t i ve in g r e di e n t s : Ar n i c a mo n t a n a 4X H PUS, Co l o c yn t hi s 4X H PUS 4 p a r t s ; Be l l a do n n a 6X H PUS, Li t hi um be n zo i c um 8X H PUS, Mus c l e t i s s ue , Po r c i n e 4C, Pr o c a i n e c hl o r i de 2X 2 p a r t s ; Co l c hi c um a ut umn a l e 6X H PUS, Cup r um s ul p hur i c um 4X H PUS, H yp e r i c um p e r fo r a t um 4X H PUS, In t e r fe r o n g a mma 4C 1 p a r t .
In a c t i ve in g r e di e n t : St e r i l e i s o t o n i c s o dium c hl o r i de s o l ut i o n . © Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
1 80
Co n t us i ve p a i n
Sp a s t i c o r c r a mp -l i ke
p a i n
Sp r a in
p a i n
•In t e r fe r o n 4C
•Pr o c a i n c hl o r ide 2X
•Mus c l e t i s s ue , Po r c i n e 4C
•Ar n i c a mo n t a n a 4X
•Be l l a do n n a 6X
•Co l o c yn t hi s 4X
•Cup r um s ul p hur i c um 4X
• Co l c hi c um a ut umn a l e 6X
•Lit hi um be n zo i c um 8X
•H yp e r i c um 4X
Mus c ul a r r he uma t i s
m
An t i -de g e n e r a t
ive c o r e
GUNA®-MUSCLE
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
1 81
GUNA®-NEURALCl i n i c a l
In di c a t i o n s
No n -s p e c i fi c br a c hi a l p a i n Br a c hi a l n e r ve p a i n due t o c e r vi c a l e n t r a p me n t In t e r c o s t a l n e r ve p a i n due t o t ho r a c i c e n t r a p me n t Po s t he r p e t i c n e ur i t i s At yp i c a l fa c i a l n e ur i t i s (Slüde r s yn dr o me , Cha r l i n s yn dr o me ) Tr i g e min a l n e ur i t i s Pa i n o f t he t e mp o r o ma n dibul a r jo i n t (TMJ) Ar n o l d s yn dr o me Ce r vi c a l , t ho r a c i c , lumba r a n d s a c r o l umba r n e r ve r o o t p a i n
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
1 82
P.N.E.I. a n t a l g ic c o r e
In fl a mma t o ry a e t i o l o g y
Va s c ul a r a e t i o l o g
yDe g e n e r a t i ve
a e t i o l o g y
• Pa i n s ymp t o ma t o l o g y r e duc t i o n by me a n s o f UP-REGULATION o f b–En do r p hi n r e c e p t o r s
• Pa i n s ymp t o ma t o l o g y r e duc t i o n by me a n s o f UP-REGULATION o f b–En do r p hi n r e c e p t o r s
• Re duc t i o n o f diffe r e n t p e r i p he r a l n e r ve s in fl a mma t i o n
• Re duc t i o n o f diffe r e n t p e r i p he r a l n e r ve s in fl a mma t i o n
Re duc t i o n o f p a i n a n d p a r a e s t he t i c p he n o me n a by me a n s o f hyp e r e me t i c a c t i o n o n n e r ve s
Re duc t i o n o f p a i n a n d p a r a e s t he t i c p he n o me n a by me a n s o f hyp e r e me t i c a c t i o n o n n e r ve s
• Tro p hi c a c t i o n o n r o o t s a n d n e r ve e n di n g s da ma g e d be c a us e o f de g e n e r a t i ve o r le s i o n a r y p he n o me n a
• Tro p hi c a c t i o n o n r o o t s a n d n e r ve e n di n g s da ma g e d be c a us e o f de g e n e r a t i ve o r le s i o n a r y p he n o me n a
• Be t a -En do r p hi n 4C
•Ka lmi a la t i fo l i a 2X
•Fe r r um p ho s p ho r i c um 2X
•Co l o c yn t hi s 4X
•Pa r i s qua dr i fo l i a 6X
•Gn a p ha l i um p o l yc e p ha lum 6X
•Ir i s ve r s i c o l o r 8X
•Ac o n i t um n a p e l l us 8X
•Fo r mi c a rufa 8X
• Ka lmi a la t i fo l i a 2X
• Mo dul a t i o n o f p a r e s i s a n d p a r a l ys i s p he n o me n a
• Mo dul a t i o n o f p a r e s i s a n d p a r a l ys i s p he n o me n a
•Ne ur o t r o p hi n 4 4C
Rhe uma t o id
a e t i o l o g y
GUNA®-NEURAL
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
P .R .M . in P ain M anagement
• Case n° 1L eft homolateral lumbago
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
P .R .M . in P ain M anagement
• Case n° 1L eft homolateral lumbago
T herapy:• G U N A ®- L U M BA R 1 ampoule
+• G U N A ®- M U S CL E 1 ampoule
+ © D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
12
34
7
6
5
L eft homolateral lumbago
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
P .R .M . in P ain M anagement
• Case n° 2T rapezius myalgia
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
P .R .M . in P ain M anagement
• Case n° 2T rapezius myalgia
T herapy:• G U N A ®- M U S CL E 2 ampoule
+• G U N A ®- N E U R A L 1 ampoule
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
T rapezius myalgia
C1C2C3C4C5C6C7
C1C2C3C4C5C6C7
1
C1
C2
C3C4C5C6C7
65
4
2
3
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
P .R .M . in P ain M anagement
• Case n° 3Whiplash
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
P .R .M . in P ain M anagement
• Case n° 3Whiplash
T herapy:
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
1 ° T reatment:• G U N A ®- N E CK 1 ampoule
2° T reatment:• G U N A ®-M U S CL E 1 ampoule
+• G U N A ®-N E U R A L 1 ampoule
Whiplash (1 ° treatment)
C1C2C3C4C5C6C7
C1C2C3C4C5C6C7
C1
C2
C3C4C5C6C7
3
2
1
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
Whiplash(2° treatment)
C1C2C3C4C5C6C7
C1C2C3C4C5C6C7
1
C1
C2
C3C4C5C6C7
4
3 2
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
P .R .M . in P ain M anagement
• Case n° 4S capular- humeral peri- artrhitis + 3 trigger points
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
P .R .M . in P ain M anagement
• Case n° 4S capular- humeral peri-artrhitis + 3 trigger points
T herapy:
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
1 ° T reatment:• G U N A ®- M U S CL E 1 ampoule
+• G U N A ®- N E U R A L 1 ampoule
2° T reatment:• G U N A ®- S HO U L D E R 1 ampoule
+• G U N A ®-P O L YA R T HR I T I S 1 ampoule
S capular- humeral peri- arthritis + 3 trigger points(1 ° treatment)
C1C2C3C4C5C6C7
C1C2C3C4C5C6C7
1
C1
C2
C3C4C5C6C7
2
3
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
1
2
3
S capular- humeral peri- arthritis + 3 trigger points(2° treatment)
o n t h e a n t e r i o r p a r t o f s h o u l d e r
o n t h e a n t e r i o r p a r t o f s h o u l d e r
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
P .R .M . in P ain M anagement
• Case n° 5A nkle sprain
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
P .R .M . in P ain M anagement
• Case n° 5A nkle sprain
T herapy:
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
1 ) T reatment of ankle:
• G U N A ®-HA N D F O O T 1 ampoule
2) T reatment of knee:
• G U N A ®- HI P 1 ampoule
A nkle sprain (1 ° treatment)
1
2
3
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
A nkle sprain (1 ° treatment)
2
3
14
5
© D i p a r t i m e n t o S c i e n t i f i c o G u n a S . p . a .
20 1
IN T E R N A L CA U S E S = M U S CL E E L O N G A T I O N – M U S CU L A R CO N T R A CT I O N - S T R E T CH I N G
T R A U M A TO L O G Y
M U S CU L A R L E S I O N S- M U S CU L A R L E S I O N S
E XT E R N A L CA U S E S = M U S CU L A R CO N T U S I O N
a c u t e p a i n , s w e l l i n g , p a i n f u l t u m e f a c t i o n , ( i n c a s e ) h e m a t o m aT H E R A P Y
- G U N A ®- M U S CL E A M P O U L E S + G U N A ®- N E U R A L A M P O U L E S- G U N A ®- M A T R I X D R O P S- G U N A ®- FL A M D R O P S
:
T H E R A P Y
- G U N A ®- M U S CL E A M P O U L E S + G U N A ®- N E U R A L A M P O U L E S- G U N A ®- FL A M D R O P S- G U N A ®- L Y M P H O D R O P S © Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
1
DROPS:
10 dro p s 3 t ime s a da y, 15 min ut e s be fo r e me a l
20 2
T E N D I N I T I S : e d e m a , h e a t , t e n d o n s t i f f n e s s
T R A U M A TO L O G Y
- T E N D I N I T I S80 % in S p o r t M e d i c i ne
• t e n d i n i t i s •t e n d o s yn o vi t i s •t e n d o p e r i os t i t i s• e t c .
T H E R A P Y
1 ) CA L CA N E A N T E N D O N :- G U N A ®-
H A N D / FO O T A M P O U L E S - G U N A ®- M A T R I X D R O P S- G U N A ®- FL A M D R O P S
4) P U BI C P A I N :- G U N A ®- H I P A M P O U L E S
- G U N A ®- FL A M D R O P S- G U N A ®- L Y M P H O D R O P S- G U N A ®- M A T R I X D R O P S
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
2
2) BICI P I T A L T E N D I N I T I S :
- G U N A ®- S H O U L D E R A M P . + G U N A- G U N A ®- FL A M D R O P S- G U N A ®- M A T R I X D R O P S
3 ) T E N D O N P A I N FR O M CA S T S :- G U N A ®- H A N D FO O T A M P O U L E S
- G U N A ®- M A T R I X D R O P S- G U N A ®- L Y M P H O D R O P S
20 3
T H E R A P Y
T R A U M A TO L O G Y
- O S T E O BI O S T M D R O P S- G U N A ®- M A T R I X D R O P S- G U N A ®- FL A M D R O P S+ G U N A ®- …. . A M P O U L E S a c c o r d i n g t o t h e a n a t o m i c lo c a l i za t i o n ( e . g . f r a c t u r e o f f e m o r n e c k : G U N A ®- H I P , f r a c t u r e o f h a n d b o n e s : G U N A ®- H A N D FO O T )
D I S L O CA T I O N S- D I S L O CA T I O N S
T H E R A P Y
- FR A CT U R E S
- G U N A ®- FL A M D R O P S- O S T E O BI O S T M D R O P S- G U N A ®- M A T R I X D R O P S- G U N A ®- L Y M P H O D R O P S - in c a s e o f s h o u l d e r d i s l o c a t i o n : a d d G U N A ®- S H O U L D E R A M P O U L E S
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
3
20 4
T H E R A P Y
T R A U M A TO L O G Y
P E R I P H E R A L N E R V E L E S I O N S- P E R I P H E R A L N E R V E L E S I O N S
T H E R A P Y
- G U N A ®- N E U R A L A M P O U L E S
- G U N A ®- FL A M D R O P S
- G U N A ®- M A T R I X D R O P S
S Y N D R O M E S D U E T O H Y P E R E XT E N S I O N- S Y N D R O M E S D U E T O H Y P E R E XT E N S I O N
- G U N A ®- N E CK A M P O U L E S
- G U N A ®- T H O R A CI C A M P O U L E S
- G U N A ®- L U M BA R A M P O U L E S
CO M P R E S S I O N S Y N D R O M E SS P R A I N S Y N D R O M E S ( BR A CH I A L P L E XU S )
P O S T O P E R A T I V E P A R E S I S
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
4
20 5
20 6
FI BR O M Y AL G I A Fib r o m ya l g i a i s n o t a new s yn d r o m e b u t a r e s u r r e c t i o n o f t h e old“d i a g n o s i s ” f i b r o s i t i s
Fib r o m ya l g i a s yn d r o m e is a v e r y c o m m o n c h r o n i c i l l n e s s w h o s e p a t h o g e n e s i s i s r e p o r t e d t o b e p o o r l y u n d e r s t o o d
Wo m e n a r e m o r e a f f e c t e d t h a n m e n
A l l r a c e s a r e a f f e c t e d
20 7
FI BR O M Y AL G I AD I A G N O S I S : t h e p a t i e n t h a s t o c o n s t a n t l y e x p e r i e n c e t h e s ym p t o m s
f o r m o r e t h a n 3 - 4 m o n t h s a n d h a v e a t le a s t 1 0 T r i g g e r P o i n t sin t o t h e 1 8 c l a s s i c a l s i t e s + d i s t u r b e d s l e e p
Commonly associated conditions: i r r i t a b l e b o w e l s yn d r o m e , m i g r a i n e ,p h yc h i c d e p r e s s i o n , o b s t r u c t i v e s l e e p a p n o e a , g e n e r a l f a t i g u e
S e v e r a l c a u s e s h a v e b e e n id e n t i f i e d : s t r e s s , t e n s i o n , c h i l l , c o n n e c t i v e t i s s u e d i s e a s e s s u c h a s
1 ) o s t e o a r t h r i t i s , n e r v e c o m p r e s s i o n , e n d o c r i n e im b a l a n c e ( e s t r o g e n d e f i c i e n c y, h yp o t h yr o i d i s m )
2) t r a u m a s , r e p e t i t i v e s t r a i n , o v e r u s e3 ) p h ys i c a l - m e n t a l f a t i g u e , a n x i e t yL A B T E S T S A N D X- R A Y : N E G A T I V E FO R S P E CI FI C D I A G N O S I S
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
20 8
T H E 1 8 P O I N T S T O T E S T
P O S I T I V E P O I N T : n e e d s t o b e p a i n f u l t o a o f 4Kg / c m 2 p r e s s u r e a p p l i e d b y t h e e x a m i n e r ’s d i g i tP O S I T I V E P O I N T : n e e d s t o b e p a i n f u l w h e n t h e a p p l i e d t h u m b p r e s s u r e i s s u f f i c i e n t t o b l a n c h t h e n a i l -b e d o f t h e d o c t o r ’s t h u m b w h e n h e / s h e p r e s s e s f i r m l y o n
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
20 9
FIBR O M Y A L G I A S Y N D R O M E
L O CA LT H E R A P Y
G U N A ®- M U S CL E +G U N A ®- N E U R A L2 a m p o u l e s (4 m l ) + 1
a m p o u l e (2 m l ) = 6 m lIN T O E A CH T R I G G E R
P O I N T : 0 . 5 m lT R I G G E R P O I N T S IN JE CT E D P E R S E S S I O N : 1 0 - 1 2
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
N U M BE R O F S E S S I O N S : 8 - 1 0
21 0
FIBR O M Y A L G I A S Y N D R O M E
H O M ET H E R A P Y
G U N A ®- FL A M D R O P S 1 5 d r o p s 3 t i m e s a d a y 9a m – 3 p m – 9p m
G U N A ®- M A T R I X D R O P S 1 5 d r o p s 3 t i m e s a d a y 9.3 0 a m – 3 . 3 0 p m – 9.3 0 p m
G U N A ®- S L E E P D R O P S 1 5 – 20 d r o p s a d a y1 0 . 3 0 p m
© Dip a r t ime n t o Sc i e n t i fi c o Gun a S.p .a .
E x a m p le :
D u r a t i o n o f t h e t h e r a p y: 2 m o n t h s